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Mechanisms of CD4 T cell antigen recognition and effector cell differentiation 
and function 
 
 
 
Abstract 
 
 The ability for CD4 T cells to efficiently search for and subsequently respond 
to microbial pathogens is essential for protective immunity, but mechanisms 
controlling these responses are not completely understood.  In this thesis I study the 
regulation of CD4 T cell responses at two different stages during an immune 
response. First, I analyze one of the most basic mechanisms by which T cells search 
for and become activated by an antigenic stimulus during the initial events in an 
adaptive immune response.   Using human memory CD4 T cells in vitro I have 
identified a novel role for actin-rich invadapodia-like protrusions (ILPs) in 
overcoming the energy barrier required for the T cell receptor (TCR) to send signals 
into T cells when interacting with peptide-loaded MHC II.  My studies show that 
ILPs, which are used during migration, are also essential for surveying the surface of 
other cells during cellular communication. Secondly, I explore the costimulatory 
requirements and function of T follicular regulatory (TFR) cells, a newly identified 
 iv 
subset of regulatory T (TREG) cells. Using mouse models, I have discovered that the 
costimulatory receptor PD-1 inhibits the differentiation and function of TFR cells in 
vivo.  My work also has revealed that TFR cells can circulate within the blood and 
that blood TFR cells can potently inhibit B cell mediated antibody production in vivo.  
Taken together, the studies presented here not only provide insights into the very 
initial events leading to adaptive immunity, but also demonstrate how adaptive 
immunity is controlled during the effector phase of an immune reaction.   
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If through science I can seize phenomena and enumerate them, I cannot, for all that, 
apprehend the world. 
Albert Camus, The Myth of Sisyphus 
 vi 
Acknowledgements 
 
 
 
Over the course of my graduate studies I have been fortunate to have met and been 
helped by so many people.  I would like to specially thank the following: 
 
To my thesis advisor, Dr. Arlene Sharpe, for taking a chance on me as an 
inexperienced graduate student, and taking the time to guide me into the scientist I 
am today.   I am forever grateful for the commitment, attention to detail and 
motherly advice that came with each and every conversation (of which there were 
many).  I am a much better scientist, as well as a much better person because of all 
your help along the way.  Thank you so much for your trust in my scientific work 
and never doubting me.  I wouldn’t have had the confidence to succeed without it. 
 
To my co-mentor, Dr. Chris Carman, for helping me along as a scientist long before 
I even started my graduate career, and particularly during graduate school where I 
learned the most.  Only because of the unlimited patience and consistent help over 
the years during many experiments have I been able to be where I am. I am also 
forever grateful for the endless professional guidance you have given me that has led 
me to pursue my PhD.  I would not have made it without you.  Chris also helped 
perform many of the experiments contained in Chapter 1.   
 
To all the lab members of the Sharpe Lab for their years of support and friendship.  
A special thank you to Dr. Loise Franscisco for years of scientific help and guidance.  
Thanks goes out to Robert Ortega, Caroline Armet, Flor Gonzalez, Dr. Dan Brown 
and Dr. Sun Lee for outstanding technical help.  More thanks goes to Sarah Hillman 
for ordering and scheduling help. 
 
To all the Carman lab members for their years of friendship and instruction during 
many a dark nights in the microscope room.  A special thank you to Laya Varghese, 
who provided technical help and performed some of the experiments in Chapter 1.  
 
To my thesis committee, Dr. Kai Wucherpfennig, Dr. Thorsten Mempel and Dr. 
Shannon Turley.  Your comments have been instrumental in guiding my projects.   
 
To John Sullivan in the flow cytometry core for all the help on sorting and analyzing 
samples.   
 
To Jennifer Lee for being there for me every step of the way and helping me stay 
sane during this process.  
 vii 
 
To all of the coauthors and collaborators on the projects presented here who have 
been instrumental in helping the projects progress.   
 
Last but not least, to my parents and family.  Only through many years of 
unwavering love and support am I able to be where I am today.  And especially to 
Dr. J.D. Sage, my grandfather, who set me on the path to scientific discovery.  
 viii 
 
Table of Contents 
 
 
 
Chapter 1. Mechanisms of Antigen Recognition by Memory/Effector T Cells..1 
 
 I.  Introduction…………...................………………………………….1 
 II. Materials and Methods………....................………………………...10 
 III.   Results……………………………………………….……………...17 
 IV.  Discussion…………………………………………………………..44 
 
Chapter 2. The role of PD-1 in controlling Lymph Node and Blood T Follicular 
Regulatory Cells…………………………………………………………………...54 
 
 I.  Introduction ………………..............……………………………….54 
 II. Materials and Methods…………….................……………………..62 
 III.   Results…………….………………………………….……………..68
 IV.  Discussion ..……………………………………………………….104 
Chapter 3.  General Discussion……………………..…………………………...121 
 
Chapter 4.  Bibliography ..………………………………………………………124 
 
Publications………………………………………………………………….……137 
 
Appendix A………………………………………………………………….…….138 
 
Appendix B………………………………………………………………….…….153 
 
 
 
 
 
 1 
 
Chapter 1. Mechanisms of Antigen Recognition by Memory/Effector T Cells 
 
 
Note: The contents of this project have been published previously1.  
 
 
Introduction 
 
Adaptive immunity relies on the ability of T cell receptors (TCRs) expressed on 
lymphocytes to efficiently recognize peptide antigen (Ag) bound to major 
histocompatibility complex (MHC) molecules 3. During the priming phase, naïve 
lymphocytes constitutively scan professional Ag presenting cells (APCs) such as 
dendritic cells and B cells within lymph nodes in order to find and respond to 
cognate antigen. Through identifying cognate antigen T cells can be activated, 
differentiate into effector cells, and perform their functions.  During the effector 
phase, memory/effector T cells need to effectively survey an extremely wide range 
of APCs and potential target cells with a broad range of phenotypic and 
morphological characteristics both within secondary lymphoid organs as well as in 
peripheral tissues in order to become reactivated. Only after reactivation can the 
memory/effector T cell then fufill its function by producing cytokines and/or lysing 
infected cells to protect the host from infection.  Fundamental cellular mechanisms 
for such immune surveillance for memory T cell reactivation remain incompletely 
understood. 
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At the heart of immune surveillance is the requirement for T cells to form extremely 
intimate (~14 nm, the total height of the TCR-MHC complex5) contacts with 
neighboring cells. This allows the TCR to directly sample the peptide antigen bound 
within the binding groove of MHC proteins and is required for detecting cognate 
antigen and triggering T cell responses. The surfaces of all cells are modified by a 
relatively thick (50-500 nm) gel-like polysaccharide coat termed the glycocalyx6, 
which provides a formidable energy barrier (via steric and electrostatic repulsion) to 
close membrane-membrane proximity, and therefore limits interaction of immune 
receptor-ligand pairs such as TCR-MHC7, 8. 
 
The glycocalyx is composed of sulfated proteoglycans, hyaluronan, glycoproteins 
and plasma proteins that come together to form a complex and dense network. Some 
proteins, such as chemokines, can be “trapped” in this dense network. Therefore, the 
glycocalyx can also convey information extracellularly to cells interacting with it. 
Glycosaminoglycans with primarily acidic side chains cause the glycocalyx to have a 
net negative charge. Therefore, not only are immune receptors buried within the 
dense glycocalyx, cells coming into close contact will be repelled from each other 
based on the negative charges of both glycocalyces.  In this way, immune receptors, 
such as TCR-MHC, are effectively shielded and immune recognition is strongly 
opposed 8-13. Thus, a fundamental question is how do T cells overcome this energy 
barrier to engage immune receptors? 
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It has long been appreciated that as a consequence of antigen recognition, specialized 
cell-cell interfaces form that involve membrane alignment, cytoskeletal remodeling, 
clustering/segregation of immune receptors/adhesion molecules and glycocalyx 
components 8, 14-18. These ‘immunological synapses’ (ISs) form within minutes of Ag 
recognition and are thought to amplify and sustain signaling, as well as facilitate 
exchange of cytokine and/or cytotoxic materials 8, 14-18. Although the mechanisms of 
TCR triggering has not been completely elucidated, it has been shown that the length 
of the TCR-MHC complex is essential in TCR signaling, and truncating or 
elongating the distance of MHC from the plasma membrane of the APC leads to 
suboptimal T cell activation19. This has lead to proposal of the kinetic-segregation 
model, where stable ISs form because TCR-MHC molecules “squeeze” out 
inhibitory molecules such as CD45.  Therefore, ISs are able to transmit signals 
because of the highly ordered orientation of stimulatory and inhibitory proteins 
contained within it.  
 
 Although many studies have focused on the orientation of ISs, the detailed 
mechanisms facilitating initial Ag sampling between T cells and APCs, and how 
these lead to early IS formation, are not completely understood 20, 21. It has been 
shown previously using preformed T cell contacts with bio-engineered substrates 
coated with MHC and a photoactivable antigen (i.e., which becomes unmasked 
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through photoconversion) that the offset time, or the time from when the antigen is 
‘un-masked’, until T cell activation is about 6.5 seconds22.  Thus, responses are 
acutely coupled to detection of antigen. However, precisely how and when antigen 
becomes initially detected in settings of cell:cell interactions remains poortly 
characterized. This stems from technical challenges associated with irregular 
topologies of APC surfaces and poorly controlled orientation of the cell-cell 
interaction planes, issues that profoundly limit the requisite imaging approaches 20, 21, 
23. 
 
Investigators have partially circumvented these restrictions by developing planar 
substrate models (i.e., lipid bilayers and antibody-coated surfaces) that provide 
optimal spatiotemporal resolution for monitoring Ag response dynamics 24-28. These 
models have afforded invaluable insights, such as the discovery of TCR micro-
clusters as the critical mediators of effective signaling and not the ISs as a whole 24-
28. However, these systems lack key features of cellular APC surfaces, such as the 
glycocalyx, topological deformability and molecular complexity. Therefore, it 
remains uncertain how to translate such findings to physiologic cell-cell immune 
surveillance.  
 
Here we employed vascular endothelial cells (ECs) as a planar antigen presentation 
cell model to interrogate the details of initial Ag recognition dynamics on a 
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physiologic cellular substrate. ECs represent the interface between the blood 
circulation and tissue and play critical roles in barrier function including regulating 
immune cell trafficking 3, 29, 30. The discovery that ECs express MHC-I, MHC-II and 
a large number of costimulatory molecules (e.g., CD40, LFA3, ICOSL, 4-1BB, 
OX40L, TL1A, PD-L1; but not CD80 and CD86) has lead to the controversial 
hypothesis that endothelium can also function as a type of APC 31-33. Indeed, several 
studies have demonstrated that endothelium can effectively re-stimulate CD4 and 
CD8 memory/effector, but not naïve, T cells 34-38. Critically, when grown in vitro, 
ECs form virtually planar cell surfaces that are ideal for high spatiotemporal 
resolution imaging of topological dynamics 39. Primary ECs can also be easily 
transfected with fluorescent constructs, something that has been extremely difficult 
in primary immune cell APCs.  Importantly, vascular endothelial cells have perhaps 
the most studied glycocalyx in biology.  Indeed, the endothelial glycocalyx has been 
shown to have essential roles as a modulator of permability, as a mechanotransducer 
of shear stress and as an inhibitor to cellular migration6.  For instance, when 
expression of a key glycocalyx component, heparin sulfate, was conditionally 
deleted from endothelial cells, there was increased rolling of lymphocytes, which 
was attributed to the lack of charge repulsion of the T cell glycocalyx 40. 
 
Taking all of the above into account, this study provides, one of the first detailed 
investigation of the initial events in CD4 and CD8 T cell scanning for and 
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recognition of Ag in the context of a physiologic APC. It had been previously 
discovered that lymphocytes actively probe the surface of the endothelium by 
dynamic insertion and retraction of sub-micron-scale, actin-rich cylindrical 
protrusions related to invadosomes 41 termed invadosome/podosome-like protrusions 
(i.e., ‘ILPs’) 39. These were demonstrated to function in supporting migratory 
pathfinding 39, 42 (Fig. 1.1). ILPs in general are formed by a wide variety of cells 
including cancer cells, monocytes, lymphocytes, smooth muscle cells and 
osteoclasts41. These structures are defined morphology and by their molecular 
composition through, yet some ambiguity still exists in their regulation and function. 
ILPs have actin cores and are enchriched in actin-associated molecules such as 
Arp2/3 and cortactin.  They also are enriched in focal adhesion proteins such as talin, 
vinculin and paxillin.  ILPs represent foci for signaling and are hot spots for tyrosine 
phosphorylation43. Typically ILPs (as few as one or more than 100 per cell, 
depending on context) form to support adherence to extracellular matrices and can be 
visualized as individual actin puncta localized between cells or between a cell and its 
substrate. The persistence of these structures can vary widely, ranging anywhere 
from tens of seconds to an hour. 
 
Transendothelial migration is an energetically unfavorable process that results in T 
cells passing through endothelial monolayers.  T cells can pass either paracellularly 
(through junctions between endothelial cells) or transcellularly (through the  
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Figure 1.1 Mechanisms for trans-cellular diapedesis. The schematic summarizing basic morphologic features 
broadly observed in vivo and in vitro as a leukocyte (tan) progressively migrates across the endothelium through 
a trans-cellular pore. A small segment of endothelium is depicted in which two individual endothelial cells are 
distinguished by green and blue coloring. Locations where specific junctional adhesion complexes (i.e., tight, 
adherens and gap junctions) form are indicated (orange). (A). Podosome Probing. The schematic depicts a 
‘snapshot’ of a lymphocyte laterally migrating toward an intact inter-endothelial junction. During migration 
dozens of actin-dependent podosome-like protrusions dynamically form (downward pointing arrows) and retract 
(upward pointing arrows), concomitantly forcing endothelial invaginations termed ‘podo-prints’. This dynamic 
protrusion behavior is thought serve in migratory pathfinding as a means of ‘probing’ the endothelial surface for 
sites permissive to trans-cellular diapedesis. I. Shows a trailing edge podosome retracting.  II. Shows a podosome 
protruding into, and being frustrated by, the rigid nuclear lamina.  III.  Shows a podosome and its cross-section 
(inset), highlighting the peripheral LFA-1 integrin/talin/vinculin zone and the actin-rich core. IV. Highlights a 
specific podosome that progressively extends to become an ‘invasive podosome’ and facilitate trans-cellular pore 
formation in panels B and C. Endothelial vesicles, VVO and caveolae (‘vesicles’) are seen enriched near or 
directly fused to podo-prints. (B). Transmigratory Cup Formation.  Overlapping temporally with podosome 
probing (A), endothelial cells proactively protrude actin-dependent, ICAM-1/VCAM-1-enriched protrusions (*) 
that embrace adherent leukocytes, forming ‘transmigratory cups’ that are thought to facilitate transition from 
lateral to trans-endothelial migration. Note many podosomes-like protrusions have or are retracting while one 
continues to protrude. (C). Trans-cellular pore formation. At permissive sites a podosome-like protrusions 
progressively extend, transitioning to ‘invasive podosomes’, which forces the endothelial apical and basal 
plasma membrane into close opposition thereby facilitating initial trans-cellular pore formation for diapedesis.  
Active SNARE complex-dependent fusion of endothelial vesicle at the site of protrusion may facilitate this 
process. (D). Pore expansion. The leukocyte progressively pushes across the trans-cellular pore causing 
expansion of its diameter to as much as 5 microns.  (E). Pore contraction.  As the leukocyte completes diapedesis 
the pore contracts, maintaining close endothelial cell-leukocyte contacts.  (F).  Pore closure/resolution. The 
leukocyte finally, exits the pore completely.  Substantial in vitro and in vivo data support the existence of rapid 
resealing of the vacated pore.  However, no details currently exist on the mechanisms of this important process. 
Taken from4. 
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endothelial cell itself).  Although paracellular transmigration has been thought to be 
the predominant mechanism by which T cells enter the tissues, there is evidence 
supporting an equal if not predominant role of transcellular diapedesis4. The first 
step of diapedesis is T cell probing the endothelium looking for sites permissive for 
transmigration. The T cell uses ILPs to interrogate the surface mechanically, 
breaking first through the glycocalyx and then indenting the plasma membrane and 
cell cortex (which is ~10-fold stiffer than the glycocalyx) (Fig. 1.1). 
 
Since the endothelium has a dense glycocalyx, which is disrupted by T cell ILPs 
during transmigration, and ILPs and ISs share some similar molecular features such 
as dependence on actin assembly, we hypothesized that ILPs may be responsible for 
initiating TCR signaling.  By using endothelial cells as a model with ideal topology 
for high spatio-temporal resolution imaging, we discovered that dynamic ILP 
probing by CD4 and CD8 memory/effector lymphocytes enforces close T cell-EC 
apposition, which facilitates Ag recognition and TCR signaling.  Moreover, T cell 
activation is sustained through a novel IS architecture dominated by dense arrays of 
calcium-stabilized ILPs (each enriched in signaling molecules) that we term a ‘podo-
synapse’. Complementary studies with model substrates and professional APCs (B 
and dendritic cells) suggest that rather than being a unique feature of T cell-EC ISs, 
ILPs are uniquely revealed in this setting. Together our results indicate that 
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memory/effector T cells use ILPs to facilitate efficient search for Ag and to help 
sustain the resulting signaling responses. 
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MATERIALS AND METHODS 
Cells 
Natural human T memory cells (nTmem) (CD4+CD45RO+CD45RA-) were isolated via 
negative selection from peripheral blood of healthy donors using a CD4 T cell isolation 
kit, followed by CD45RA+ cell depletion (Miltenyi Biotec) to >95% purity and used 
within hours of isolation. Induced/expanded human T memory cells iTmem 
(CD4+CD45RO+) were made by culturing peripheral blood buffy coats for 72 hrs in 1 
mg/ml of bacterial superantigens staphylococcal enterotoxin B (SEB) and toxic shock 
syndrome toxin 1 (TSST) (Toxin Technology) in RPMI complete media. CD4 memory 
cells were enriched by using a CD4 T cell memory negative isolation kit (Miltenyi 
Biotec).  Cells were cultured 3-10 days in 20 ng/ml IL-15 (R&D Systems) in RPMI 
complete media to maintain memory phenotype.  
 
Mouse CD4 or CD8 T cells were isolated by magnetic separation from either 
OTII+TCRa-/-CD45.1+/+ (crossed from OTII mice from Taconic Farms) or 
OTI+Thy1.1+/+ (crossed from OTI mice from Taconic Farms) mice and activated with 
irradiated splenocytes in the presence of 30 µg/ml OVA 323-339 (OTII) or 500ng/ml 
OVA-SIINFEKL (OTI) supplemented with IL-2 for 3 days. T cells were reselected with 
CD4 magnetic beads and rested in culture in the presence of IL-2 for a further 3 days. 
Human Lung Microvascular ECs (HLMVEC), Human Dermal Microvascular ECs 
(HDMVEC) and Human Umbilical Vein ECs (HUVEC) were from Lonza and cultured 
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on fibronectin (10 mg/ml; Invitrogen) in EBM-2 MV media (Lonza). Mouse Heart ECs 
were isolated from C57Bl/6 mice by collagenaze digestion of heart tissue of 9-15 day 
old mice with 500U/ml collagenase for 30 min. followed by positive selection with anti-
CD31(MEC13.3) coated beads (Dynal). ECs were cultured for 7 days in media with EC 
Growth Supplement (Biomedical Technologies) followed by reselection with beads 
coupled to anti-CD102. ECs were >95% purity based on expression of CD105+CD102+. 
ECs were transfected by Amaxa electroporation according to manufacturers instructions 
(Lonza). Palmitoylated YFP (“Mem-YFP”) and soluble monomeric DsRed (sDsRed) 
constructs were from Clontech. Palmitoylated DsRed (Mem-DsRed) and ICAM-1-GFP 
were generated as described 39. ECs were activated for 48 hr with 100 ng/ml IFN-γ 
(R&D Systems) and 12 hr with 50 ng/ml TNF-α (R&D Systems). The Priess B cell line 
was a kind gift from Dr. Kai Wucherpfennig. Chinese Hamster Ovary (CHO)-K1 
epithelial cells were from ATCC and were transfected by Amaxa electroporation. 
Murine bone marrow-derived dendritic cells (BMDCs) were prepared from bone 
marrow cells isolated from femurs and tibias of C57Bl/6 or Ciita–/– mice (Jackson Labs) 
and cultured in 30 ng/ml GM-CSF (Peprotech) for 6 days.  Cells were transfected with 
constructs by Amaxa electroporation.   
 
Transendothelial Migration 
Lymphocyte transendothelial migration assays were conducted in both static and shear 
conditions as described 39. In general, endothelial cells were plated to 90 percent 
confluency on fibronectin-coated coverslips and cultured for 72 hours with 100ng/ml 
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IFN-γ and overnight with 50ng/ml TNF-α in EBM-2 media (Lonza).  ECs were washed 
twice and T cells were added in imaging buffer (HBSS with 1% human serum albumin, 
1mM HEPES, 1mM Ca2+ and 1mM Mg2+). In some cases T cells were added to 8 mm 
pore transwell inserts that were pre-seeded with ECs and then collected from the bottom 
chamber 6 hr later and analyzed by flow cytometry. 
 
Live-cell Imaging and Analysis 
Live cell imaging was performed on an Axiovert S200 microscope with a 40x oil 
objective and analyzed with Axiovision software (Zeiss). For calcium imaging, T cells 
were pre-incubated with 1 µg/ml Fura-2-AM or Fluo-4-AM (Invitrogen) for 30 min. For 
Fura-2, standard Fura-2 filters were used according to manufacturers instructions 
(Chroma) and ratiometric calcium flux was calculated (340nmEX-510nmEM-
background/380nmEX-510nmEM-background) for each cell using Axiovision. For Fluo-
4, green fluorescence filters were used and basal fluorescence signal was established by 
imaging cells on uncoated chambers. T cell polarity was calculated from bright field 
images as the ratio of the greatest edge-to-edge dimension in the x-y plane (i.e., the long 
axis) divided by the perpendicular axis. Migration velocity was measured for cells using 
the Axiovision Cell Tracking Module. Podo-print/ILP lifetimes were assessed using 
podo-print appearance and disappearance on mem-dsRed- or mem-YFP-transfected ECs 
as a readout for the presence of ILPs 39. Podo-print/ILP lifetimes were calculated as: the 
last time point when an individual podo-print/ILP was visible – the time point when that 
podo-print/ILP first appeared. Podo-print/ILP lateral translocation was assessed by 
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determining the distance between the T cell centroid and the first and last positions of 
an individual podo-print/ILP during its lifetime. Podo-print/ILP index, a measure of the 
total number of ILPs per cell, was calculated at 5 min post addition of T cells. ‘Offset 
Time’ was used to describe relative time between first podo-print/ILP formation and 
calcium flux rise above background. Temporal resolution was limited to 10 seconds, the 
maximal achievable acquisition frame rate of this analysis. Data was then sorted into 10 
second interval bins. 
 
For selected studies, lymphocyte were pre-incubated, or lymphocyte and APCs co-
incubated, with select pharmaceutical agents, incuding latrunculin-A (1 µg/ml, Sigma), 
PP2 (10 µM, Calbiochem), BAPTA-AM (40 µM, Sigma), BTP2 (20 µM, Calbiochem), 
thapsigargin (1µM Sigma), CAMKII inhibitor CK59 (50µM, EMD Biosciences) as 
indicated. For calcium blockade conditions, T cell were pretreated with BAPTA-AM 
and BTP2 in imaging buffer containing high (45 mM) potassium. T cells were added to 
ECs and imaged with additional BTP2 for the duration of imaging. 
 
Fixed-cell Imaging 
Fixed cell samples were imaged on a LSM 510 confocal microscope (Zeiss) with a 63x 
dipping objective. Samples were fixed and stained for αL integrin (TS2/4), ICAM-1 
(IC1/11), F-actin (phalloidin), MHC II (WR18, Abcam), PKC-θ, talin (rabbit anti-talin, 
a gift from Dr. Keith Burridge), CD3 (OKT3, ebioscience), CD43 (L60, BD 
Biosciences), CD45 (HI30 or UCHL1, ebioscience), HS1 (clone 9, BD Biosciences or 
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rabbit anti-HS1, Cell Signaling), ZAP-70 (Santa Cruz), P-Y (4G10 platinum, Millipore) 
or NFAT (BD Biosciences). Transmigration was analyzed by confocal microscopy as 
described 44.  Z-stack images were taken at 0.5µm intervals through endothelial 
monolayers with T cells.  Position of transmigration was quantified by scrolling through 
z-stack images and identifying LFA-1/Actin positive T cells.  T cells that were adherent 
to endothelial monolayers with no transcellular pores were identified as adherent.  T 
cells that had transcellular pores (LFA-1/Actin rich structures protruding into and 
through the endothelial monolayer which displaces endothelial ICAM-1) were 
identified as transmigrating.  T cells that were completely underneath the endothelium 
without any transcellular pores present were identified as transmigrated.  Areas of non-
continuous endothelial monolayers were omitted.   
 
CTL Killing Assay 
For specific killing assay, murine ECs were labeled with either 0.6µM or 0.02µM CFSE 
(CFSEhi and CFSElow, respectively). The CFSEhi population was pulsed with 1µg/ml 
SIINFEKL for 20 minutes and washed extensively. Both CFSEhi and CFSElow 
populations were plated together in a 1:1 ratio overnight. Activated OTI CD8 T cells 
were rested for 5 hours and added to monolayers in a 3:1 T cell:target cell ratio. 
Cultures were trypsinized, and were stained for CD105 to differentiate the ECs from T 
cells, and analyzed by flow cytometry. Specific lysis was calculated by the following 
equation (1-((CFSEhi /( CFSEhi + CFSElow))/(control CFSEhi/CFSElow))*100). 
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Planar Coated-Glass APC Model 
Coated glass immune synapse (IS) models were prepared as described 25, 45. Briefly, 
imaging chambers were coated with ICAM-1-Fc (10 µg/ml; R&D Systems) alone, or 
together with anti-CD3, anti-CD43, anti-CD45 or control IgG antibody (10 µg/ml). 
Fluo-4-labelled lymphocytes were added and imaged by fluorescence and interference 
reflection (IRM) microscopy. 
 
Coated-Cell APC Model 
CHO-K1 cells were transfected with ICAM-1-GFP and soluble dsRed via 
electroporation using the Amaxa electroporation system. Cells were then coated with 
antibodies via a biotin/steptavidin (SA)-based approach 46. For this, cells were subjected 
to primary amine-targeted cell surface biotinylation for 15 min with biotin-NHS-ester 
(Thermo Electron) (0.5 µg/ml). Cells were washed and then incubated with unlabeled 
streptavidin, at 10 µg/ml for 15 min. Cells were then washed and incubated with 
biotinylated anti-CD3, -CD43 or -CD45 (eBiosciences) at 10 µg/ml for 15 min. Surface 
coupling was determined by using a fluorescent anti-mouse antibody and visualized on 
the microscope.   
 
T cell Activation by CD3 Cross-linking 
Fluo-4- labeled T cells were settled onto uncoated glass chambers and 10µg/ml anti-
CD3 and CD28 were added to the imaging chambers and calcium was monitored. 
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Transmission Electron Microscopy 
Transmission electron microscopy of T cell-APC complexes was performed as 
described 39. EC monlayers were fixed with 2.5% glutaraldehyde and 2% 
paraformaldehyde in 1.0M sodium cacodylate buffer (pH 7.4) for 2 hours, post-fixed in 
1.5% sym-collidine-buffered OsO4 for 1 hour, stained en bloc with uranyl acetate, 
dehydrated with sequential washes in increasing alcohol concentrations and embedded 
in Eponate.  Samples were lifted with a short exposure to liquid nitrogen and 
reembedded so that the EC monolayers were perpendicular to the face of the block.  
90nm sections were cut with and imaged with a Phillips CM-10 electron microscope at 
80kV.  50 randomly selected micrographs were analyzed by enumerating zones of 
membrane apposition (<20 nm) and correlating them with respect to ILP location.  The 
electron microscopy was carried out in collaboration with Dr. Ann Dvorak and Tracey 
Scuito.   
 
Statistical Analysis 
Error bars represent standard error or standard deviation as indicated. P values were 
calculated via unpaired Student’s T tests in Graphpad Prism. Statistical significance is 
indicated with p values as follows: *** = p<0.0005, ** = p<0.005, * = p<0.05. 
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Results 
 
Endothelial-Presented Ag Promotes Activation of CD4 Memory T cells 
 
We wanted to elucidate the mechanisms by which memory/effector T cells initially 
probe for and recognize Ag utilizing endothelial cells as model APCs. Although T cell 
lines such as Jurkat T cells have been used extensively to study IS architecture, we had 
found that they do not effectively interact with vascular endothelial cells in vitro. 
Therefore, we isolated natural CD4 memory-like lymphocytes (nTmem) and generated 
induced/expanded CD4 memory-like lymphocytes (iTmem), from human peripheral 
blood.  Since nTmem are used directly after isolation from human subjects, they are the 
most physiological responder T cell that we can use.  We cultured iTmem so that we 
could expand out this population in order to perform experiments that require larger 
numbers of cells. The isolated nTmem were CD4+, CD45RO+ and contained both 
central-memory (TCM)- and effector-memory (TEM) T cells (~78% and ~22%, 
respectively) based on CD62L staining (Fig. 1.2). The iTmem were slightly more 
polarized toward the TEM subtype (~69% vs. ~31%) (Fig. 1.2). Monolayers of 
HLMVECs (Lung ECs), HDMVECs (Skin ECs) and HUVECs (Umbillical ECs) were 
used as models for the vasculature. In vivo endothelial MHC-II expression is dependent 
on IFN-γ 31. This was recapitulated in vitro by culturing ECs with exogenous IFN-γ 
(Fig. 1.2). Endothelium was additionally activated with TNF-α to promote an inflamed 
phenotype by upregulation of ICAM-1.   
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Fig. 1.2. Phenotype of Memory-like CD4 T cells and Endothelium (A) CD4 nTmem cells were 
sorted from human blood according to Materials and Methods, stained for indicated surface 
markers and analyzed by flow cytometry. (B) Surface phenotype of cultured induced T memory 
cells (iTmem). CD4 T cells were isolated, activated and cultured according to Experimental 
Procedures, stained for indicated surface markers and analyzed by flow cytometry. Plots are only 
CD4 positive gate. (C). HLMVEC were incubated with or without IFN-γ for 48 hours and with or 
without TNF-α for 18 hours, trypsinized, stained for MHC II, and analyzed by flow cytometry.  
Copyright 2012 The American Association of Immunologist, Inc. 
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Next, we set up live cell analysis to concomitantly monitor T cell activation (i.e., 
calcium flux) and migration on endothelium pulsed with Ag (i.e., bacterial super-
antigen, a widely used model Ag 45, 47, 48). Superantigens bind the TCR and MHC II 
outside of the TCR-MHC binding pocket to elicit activation.  In this way, we could 
circumvent the need for MHC matching of endothelial donors, which can be 
cumbersome and costly.  In the absence of Ag, nTmem and iTmem fluxed little calcium 
(Fig. 1.3A.), remained polarized (Fig. 1.3B), and underwent continuous lateral (Fig. 
1.3C) and transendothelial migration (i.e., ‘diapedesis’) consistent with their 
designation as memory cells (Fig. 1.3D). On HLMVECs pulsed with Ag (1 µg/ml SEB 
and TSST), T cells rapidly fluxed calcium, lost polarity and arrested migration (Fig. 
1.3A-C). Similar results were found with alternate Ag (e.g., SEE (staphylococcal 
enterotoxin E) and MAM (mycoplasma arthridic antigen) presented by HDMVECs or 
HUVECs (data not shown). Additionally, in the absence of Ag, the majority of iTmem 
transmigrated within 30 min, whereas in the presence of Ag, diapedesis was delayed by 
~30-60 minutes (Fig. 1.3D). Thus, the migratory stop signal was transient. ITmem also 
exhibited Ag-dependent transient migration arrest under laminar fluid shear flow 
conditions similar to those found in microvasculature in vivo (2 dyne/cm2; Fig. 1.3E-G). 
 
During T cell activation the transcription factor NFAT is dephosphorylated by 
calcineurin and translocates from the cytoplasm to the nucleus, where it stimulates 
transcription49. Incubation of nTmem on Ag-pulsed ECs promoted robust nuclear  
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 Fig. 1.3 Human Microvascular ECs are Capable of Ag-specific Stimulation of CD4 
Memory-like T Cells. (A) Human CD4 nTmem (circles) or iTmem (triangles) were loaded with 
Fura-2 and incubated on Ag-pulsed HLMVECs. Calcium flux at 5 min (left) or at maximal value 
over a 30 min duration (right) were plotted. (B and C) iTmem were incubated on HLMVEC pulsed 
with Ag and T cell polarity (length/width ratio) at 5 min and velocity was calculated over a 30 
min duration. (D) iTmem transendothelial migration was scored on Ag pulsed ECs as described in 
Materials and Methods. (E) iTmem were infused over Ag pulsed HLMVEC at 2 dyne/cm2 and 
imaged. Depicted is an end-point image with migration tracks of apical (blue) and transmigrated 
(red) lymphocytes. (F and G) Lateral migration velocities for T cells from (E) during both pre- 
and post-diapedesis phases of migration over 30 min (F) and percent of iTmem transmigrated 
were measured (G).  (H) Representative images of nTmem incubated on Ag-pulsed HLMVEC and 
staining for actin (green), NFAT (red) and nucleus (blue).  (I) nTmem were incubated on activated 
HLMVEC. Nuclear NFAT translocation was scored according to line scan profiles (left).  (J) 
Samples were acquired as in (H) and representative transmigrating or transmigrated (‘Under’) 
lymphocytes are shown.  Scale bar = 5 µm. Data represent mean + SD (B, C) or SEM (D, F, G, 
I).  *p<0.05, **p<.005, ***p<0.0005. Copyright 2012 The American Association of 
Immunologist, Inc. 
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translocation of NFAT (Fig. 1.3H, I). Significantly, transmigrating nTmem and iTmem 
cells retained nuclear NFAT demonstrating that these cells remained activated even 
after transmigration (Fig. 1.3J). NTmem on endothelium that was pulsed with Ag, but not 
pretreated with IFN-γ (and therefore lacked strong MHC-II expression) exhibited little 
NFAT translocation (Fig. 1.3I) confirming that the responses to Ag-pulsed endothelium 
were MHC-II-dependent. Additionally, cells that transmigrated through vascular 
endothelium that was pulsed with sAg secreted IFNγ, and therefore were fully activated 
(data not shown).  Collectively these results demonstrate that endothelium is able to 
present model Ag in an MHC-II-dependent manner to primary CD4 memory/effector 
lymphocytes, which induces a transient delay in diapedesis and full T cell activation. 
 
ILP Arrays Dominate the T Cell-Endothelial Cell Interface During Activation 
 
Next we investigated the cellular and molecular basis for T cell activation in our 
endothelial APC model. Previously, we transfected fluorescent membrane markers 
(‘mem-YFP’ or ‘mem-DsRed’) expressed in the ECs to detect topological changes in 
the plasma membrane 39. In this way, we demonstrated that ~0.5 mm fluorescent rings 
that formed dynamically on the endothelium under migrating T cells corresponded to 
cylinder-shaped cell surface invaginations (i.e., ‘podo-prints’) induced by lymphocyte 
Invadosome/Podosome-Like Protrusions (ILPs). Thus, podo-prints formed on the EC 
surface served as an indirect, but extremely sensitive, read-out for T cell ILPs 39.  Direct 
readout of T cell ILPs by transfection of T cells was not possible because primary T 
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cells are difficult to transfect and large local volumes of the T cell membrane lead to 
oversaturation of fluorophores at the endothelial interface, and therefore, suboptimal 
imaging.  
 
In the current study, we similarly observed in control settings that podo-prints formed 
and disappeared continuously (with lifetimes of tens of seconds) under the leading edge 
lamellipodia of migrating iTmem (Fig. 1.4A, C). Strikingly, when ECs were pulsed with 
Ag, iTmem rapidly formed dense arrays of podo-prints largely localized at the periphery 
of the T cell-EC interface under symmetrical lamellipodia (Fig. 1.4, Ex1). A minority 
(~20-30%) of the iTmem cells formed rosette type podo-print arrays that lacked bias for 
the cell periphery (Fig. 1.4B, Ex2). In both cases, podo-prints/ILPs were significantly 
stabilized (lifetimes of ~18 min; Fig. 1.4C).  Podo-prints/ILPs exhibited limited lateral 
translocation, a process that is currently visualized during formation of traditional ISs 
(0.31 + 1.5 mm; Fig. 1.4D-F). After ~30 min of contact, ILPs began to disappear and T 
cells initiated transmigration. 
 
As confirmation that the above observations reflected three-dimensional podo-prints in 
response to T cell ILPs probing the surface and not retraction of membrane away from 
the T cell, we co-transfected endothelium with mem-DsRed along with soluble GFP 
(sGFP) as a marker for cytoplasmic volume 39. This showed individual fluorescent 
membrane rings of each podo-print, in fact, represented cytosol-displacing 
invaginations into the EC surface.  This demonstrates that the podo-prints form because  
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Fig. 1.4 CD4 Memory-like T cells form Stabilized Arrays of ILPs on Ag-Presenting 
Endothelium. (A and B) HLMVECs were transfected with mem-YFP or mem-DsRed, 
activated and pulsed without (A) or with (B) Ag (TSST/SEB). iTmem were imaged live 
upon addition to ECs. Individual frames at selected time intervals are shown. Arrows 
indicate fluorescent rings formed on endothelium under adherent lymphocytes. (C) 
Podo-print/ILP lifetimes from imaging studies as in (A and B). Data represents mean + 
SEM of at least 80 ILPs formed by at least 25 cells from three or more separate 
experiments. (D) Schematic representation of podo-print/ILP lateral translocation 
analysis. Grey ‘T cell outline’ represents a T cell-EC contact area with the ‘T cell 
centroid’ indicated as a blue circle and individual podo-prints indicated as black rings. 
The linear distance between the centroid and podo-print was measured at both the first 
and last appearance of an individual podo-print/ILP during its lifetime.  (E and F) Podo-
print/ILP distances were measured as in (D). Distances from the cell centroid at time of 
formation and disappearance were plotted for individual podo-prints (E). Data from (E) 
were further processed to report change in distance (F). Scale bars= 5 µm. Copyright 
2012 The American Association of Immunologist, Inc. 
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of ILP pushing into the surface of the endothelium (Fig. 1.5A). Furthermore, confocal 
imaging showed that podo-prints were ICAM-1-enriched cylindrical EC invaginations 
into which T cell ILPs extended (Fig. 1.5B). ILPs were enriched in the integrin LFA-1 
(Fig. 1.5B), F-actin (Fig. 1.5C) and talin (Fig. 1.5D), similarly to 
podosomes/invadosomes 41, 42. Analogous structures formed under physiologic shear 
flow, with diverse ECs (including HLMVECs (Fig. 1.5A, C and D), HUVECs (Fig. 
1.5B), HDMVECs (not shown)), with nTmem (data not shown) and with alternate Ag 
(Fig. 1.5B)). Similar structures also formed when previously activated murine OT-II 
CD4+ T cells were incubated on heart microvascular ECs pulsed with OVA 323-339 
peptide Ag (data not shown).  Thus, memory T cell usage of ILPs to probe for antigen 
and ILP stabilization due to T cell activation is not only relevant for human memory 
CD4 T cells, but also occurs in primary murine models.   
 
To assess the T cell-EC interaction in greater detail, we utilized transmission electron 
microscopy in collaboration with Dr. Ann Dvorak. In the absence of Ag, ILPs averaged 
430 + 34 nm in depth and 348 + 33 nm in width (Fig. 1.5E, F). In the presence of Ag, 
ILPs were similar in morphology and size (depth = 437 nm, width = 277 nm), but 
tended to form in denser clusters (Fig. 1.5E-G). An important feature of the ILPs, 
whether in the absence or presence of Ag, was the existence of zones of extremely close 
T cell-EC apposition, typically at the tips of the ILPs as if driven by ILP extension (Fig. 
1.5F, G, arrows). Though not exclusive to these locations, quantitative analysis revealed 
that intercellular contacts of <20 nm were 9-fold greater at ILP tips compared to other  
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Fig. 1.5 Ag-Stabilized ILPs Exhibit a Discrete 3D Architecture. (A) Ag-stabilized T 
cell ILPs protude into the EC surface. Imaging was conducted as in (Fig. 1.4B) on 
HLMVECs co-expressing soluble, cytoplasmic GFP (green) and mem-DsRed (red). 
(B) 3D reconstruction from confocal imaging of podo-prints and ILPs. iTmem were 
incubated for 20 min on activated Ag-pulsed (SEE) HUVEC and then fixed, stained for 
ICAM-1 (green) and LFA-1(red) and imaged by confocal microscopy. Sections were 
digitally reconstructed and projected as 3D renderings. Inset (b) provides a magnified 
view of the ILP arrays. Inset (b’) provides an orthogonal cross-section. (C and D) Ag-
stabilized ILPs are enriched in actin and talin. Mem-YFP(C; green)- or mem-DsRed (D; 
red)-transfected HLMVEC were pulsed with Ag (TSST/SEB) and incubated with iTmem 
for 5 min and stained for F-actin (C; red) or talin (D; green). (E) Quantitation of 
ultrastructural depth and width of T cell ILPs. Samples as in (C) were imaged by electron 
microscopy and ILPs were measured. Data represent mean + SEM from at least 100 ILPs 
from at least 20 representative micrographs per condition. (F and G) ILPs enforce close T 
cell-EC membrane apposition in the absence and presence of Ag. T cell and endothelial 
nuclei are indicated with red and green overlays, respectively. Arrows and inset (a) 
highlight regions of extremely close lymphocyte-EC membrane apposition enforced at the 
ILP tips.  Scale bars in A-D represent 5 µm and in F-G represent 500 nm. Ns = not 
significant, *p<0.05. Copyright 2012 The American Association of Immunologist, Inc. 
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regions. The idea that ILPs can exert significant force is supported by their ability to 
both drive trans-cellular diapedesis 39 and to displace/deform organelles such as the 
nucleus (Fig. 1.5F).  It is at these locations at the tips of the ILPs, where it seems like 
the most force is generated. Therefore, we believe that the very tips of the ILPs are the 
locations where initial TCR signals are triggered.  
 
Ag-Stabilized ILPs Share Features of Traditional TCR Signaling Micro-clusters 
 
To address how these ILP-dominated cell-cell interfaces relate to TCR signaling and if 
the ILP tips were spots for TCR signaling we stained for traditional IS markers 18, 25, 26. 
Confocal microscopy revealed that podo-prints formed on the surface of the 
endothelium were modestly, but consistently, enriched in MHC-II compared to MHC-I 
or mem-YFP (Fig.1.6A, B). T cell ILPs were enriched in CD3 which is the dominant 
signaling component of  the CD3/TCR complex (Fig.1.6C). In some instances the CD3 
was enriched precisely at the tip of the ILP (Fig. 1.6C inset b1) and in other cases 
enriched at the outer edge of the ILP (Fig. 1.6C inset b2).  Interestingly, both examples 
can be found on the same cell, and may reflect ILPs that are in different stages of 
formation.  Comparable CD3 enrichment formed under physiologic shear flow 
(Fig.1.6I, J). In <5% of T cells CD3 was distributed into a cSMAC-like cluster rather 
than in peripheral ILPs (Fig. 1.7).  
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Fig. 1.6 Ag-Stabilized ILPs are Foci for Immune Signaling.  ITmem cells were incubated 
with activated, Ag-pulsed (TSST/SEB) HLMVEC for 5 min, fixed, and stained as 
indicated and imaged by confocal microscopy. (A) Ag stabilized ILPs (F-actin, green) 
protrude into MHC-II (red)-enriched podo-prints. Arrows indicate MHC-II-enriched podo-
prints. (B) Samples as in (A) were stained for MHC-II (HLA DR/DP/DQ; red) and MHC-I 
(HLA A/B/C; green). Schematic of gated regions of interest is shown on the left, and 
included a region outside of the IS (I), the ILP-rich region of the IS (II) and the central 
region of the IS (III). Right panels show pixel fluorescence intensity histograms for 
regions I-III. (C) ILPs (F-actin, blue) protruding into podo-prints (mem-YFP, green) are 
enriched in CD3 (red). Within individual ILPs CD3 is predominantly focused at the tip 
(insets b1) and to a lesser extent the edge (inset b2). (D) PKC-θ(red) is enriched with CD3 
(green) in ILPs. (E-G) ILPs (F-actin, blue) colocalize with ZAP-70 (E; red), phospho-
tyrosine (F; red) and HS1 (G; red). (H) HS1 (red) is highly enriched in ILPs. Cross-
sectional views from serial-section confocal microscopy are shown of a lymphocyte 
adherent to the endothelium presenting Ag. (I and J) ILP arrays were allowed to form as 
above with the additional presence of physiologic laminar fluid shear flow (2.0 dyne/cm2, 
arrow indicates direction). (I) MHC class II (red) and f-actin (green) are shown. (J) CD3 
(red) and ICAM-1 (green) are shown. Scale bars = 5µm. Copyright 2012 The American 
Association of Immunologist, Inc. 
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Fig. 1.7 Distribution of Immune Signaling Molecules in the T cell-EC IS.  ITmem cells were 
incubated with activated, Ag-pulsed (TSST/SEB) (and ICAM-1-GFP or mem-YFP-
transfected, where indicated) HLMVEC for 5 (A, B, D) or 30 min (C), fixed, and stained as 
indicated and imaged by confocal microscopy. (A) Samples on mem-YFP (green)-transfected 
ECs were stained for MHC-II (red). Representative micrograph is shown on the left. Middle 
panel indicates fluorescent values of each channel from line scan (dashed line on left). Right 
indicates quantitation of fluorescence intensities along the dashed line comparing podo-prints 
from nearby regions of endothelium outside of the T cell contact zone. (B) Samples were 
prepared as in (A) on ICAM-1-GFP or mem-YFP-expressing HLMVECs and stained for CD3, 
CD43 or CD45 and LFA-1 as indicated. En face (x-y) and orthogonal cross-sectional (x-z, y-z) 
views are depicted. CD3, CD43 and CD45 are pseudo-colored using a rainbow intensity 
indicator (blue = low, red = high). Left panels show a relatively basal section (see yellow 
arrows) at the T cell-EC interface where the podo-print- and ILP arrays are evident (red 
arrows). Right panel shows a section that is relatively more apical (i.e., distal from the IS, see 
orange arrows). Note that CD3 has highest intensity within the ILPs compared to parallel 
oriented segments at the edge of the cell in regions outside of the IS (i.e., the D-SMAC). By 
contrast, CD43 and CD45 intensity is highest outside of the IS (i.e., in the D-SMAC), shows 
modest levels within the peripheral ILP region and is lowest in the center if the IS. (C) 
Samples were stained for F-actin (blue), LFA-1 (green) and CD3 (red). Whereas, on the 
majority of T cells CD3 was either enriched into ILPs after 30 min (upper panels), only a very 
small fraction (<5%) of cells displayed enriched into cSMAC-like central clusters. A similar 
fraction showed relatively more diffuse distributions (data not shown). (D) Samples were 
stained for F-actin (green and rainbow intensity pseudo-color) and PKC-θ (red and rainbow 
intensity pseudo-color), subjected to confocal microscopy and presented as en face and 
orthogonal projections. Scale bars represent 5 µm. Copyright 2012 The American Association 
of Immunologist, Inc. 
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Molecules implicated in TCR signaling, including PKC-θ (Fig. 1.6D), ZAP-70 (Fig. 
1.6E) and phosphotyrosine (P-Y; Fig. 1.6F) were also enriched in ILP cores, suggesting 
active signaling of immune receptors at these sites. Importantly, the phosphorylated 
tyrosine that is enriched here is also a general feature of podosomes. The cortactin 
homolog hematopoietic lineage cell-specific protein 1 (HS1), a known regulator of both 
podosomes and ISs 45, 50-52 showed particularly strong enrichment within the ILPs (Fig. 
1.6G, H). Alternatively, the inhibitory molecules CD43 and CD45 localized primarily to 
the region outside of the T cell-EC interface consistent with the kinetic segregation 
model for ISs present in ILPs (Fig. 1.7B). These observations suggest that ILPs may 
serve as discrete loci for TCR signaling with general features similar to TCR signaling 
micro-clusters and ‘multi-focal’ synapses that have been previously reported 18, 26, 27, 53-
55. 
 
Collectively, these experiments show that CD4 iTmem activation due to EC MHC-II/Ag 
is coupled to cell-cell interfaces dominated by arrays of ILPs that are stabilized and 
subsequently enriched in TCR signaling molecules and podosome proteins. We term 
this previously undescribed architecture, which shares features of both podosome 
belts/rosettes and multi-focal ISs, a ‘podo-synapse’.   
 
ILPs Support Efficient Ag Recognition and Sustained Signaling 
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To determine the functional relationship between ILP formation and T cell activation, 
we concomitantly monitored calcium flux and ILP dynamics. In the presence of Ag, a 
small amount of calcium flux was evident shortly after the first appearance of ILPs.  
These initial ILPs tended to form within seconds and at the center of the cellular 
interface between the T cell and endothelial cell and had a high turnover. After an initial 
low calcium flux signal which occurred after the first ILPs, calcium flux then peaked 
several minutes later and gradually decayed over the following 5-60 min (Fig. 1.8A-B). 
Calcium flux always occurred subsequent to (or in the same 10 sec interval as) the 
appearance of at least one ILP, with an average offset time of ~25 seconds (Fig. 1.8C). 
In turn, stabilized ILP arrays became evident in the ~30-60 seconds following the rise in 
calcium (Fig. 1.8A, B).  Interestingly, during ILP stabilization, calcium flux continued 
to increase and then peaked seconds after the ILP array formed completely.  After this 
time few new ILPs were detected, and calcium flux was maintained at the maximum 
level.   
 
These observations suggested that the close intercellular contacts driven by ILPs may 
promote initial Ag recognition and TCR triggering. Testing this hypothesis is 
challenging as both ILPs and TCR signaling are fundamentally dependent on F-actin 
assembly and many of the same actin regulatory pathways 39, 41, 56. Thus, we simply 
compared effects of F-actin inhibition (via latrunculin-A) on T cell activation by an Ag-
pulsed APC versus direct TCR cross-linking. When stimulated by Ag-pulsed ECs, 
iTmem pretreatment with latrunculin-A caused 100% blockade of both ILP formation and  
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Fig. 1.8. T Cell ILP Formation Precedes Ag Recognition. (A) ITmem were labeled 
with Fura-2 and imaged live (at a maximal temporal resolution of 10 seconds) during 
migration on mem-DsRed-transfected, Ag-pulsed HLMVECs. Upper panels show mem-
DsRed. Arrows indicate initial ILP formation. Middle panels indicate calcium flux 
values on a rainbow scale. Lower panels provide a schematic representation of newly 
formed (green) and previously formed (in relation to previous field; red) podo-prints. ‘a’ 
is the frame of initial ILP/podoprint. ‘b’ is the frame when calcium flux rises above 
background. ‘c’ is the frame when the peripheral ILP array is stabilized. Note this 
correlates with peak calcium flux. (B) Graphical representation of calcium flux with 
frames a-c noted. (C) Quantitation of ILP-calcium flux offset time. Live-cell imaging 
was as in (A) and offset time (time from when first ILP forms until calcium flux rises 
above background) was calculated. Data was binned into 10 second intervals and 
average +/- SEM is shown for 35 individual T cells from three separate experiments. 
Scale bars represent 5µm. Copyright 2012 The American Association of Immunologist, 
Inc. 
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calcium flux during the first 5 minutes of co-incubation (Fig. 1.9A, B). By contrast, 
when TCRs were stimulated directly by anti-CD3/CD28 cross-linking, significant 
(though attenuated by ~60%), immediate calcium flux was elicited in the presence of 
latrunculin-A (Fig. 1.9 C,D), as shown previously 57.  From this we conclude that the 
total latrunculin-A-induced blockade of early response of T cells to Ag-pulsed ECs 
reflects a defect in ILP formation (Fig. 1.9 C,D). We speculate that the moderate 
attenuation of calcium signals seen with latrunculin-A treatment on CD3 crosslinking 
may still be due to blockade of ILP formation, as the mechanism of CD3 crosslinking to 
achieve TCR signaling may still partially involve force-based triggering elicited by 
structures such as ILPs.   
 
Calcium Flux is Necessary and Sufficient for Ag-Mediated ILP Stabilization 
 
Next we investigated the transition from dynamic ILP probing to formation of stable 
ILP arrays. Given the correlation between rise in calcium and appearance of ILP arrays 
we hypothesized that calcium may be key for stabilizing ILPs. To test this we sought to 
prevent calcium flux downstream of TCR signaling to determine if we can block ILP 
stabilization.  Initially, pretreating T cells with the widely used calcium chelator 
BAPTA resulted in normal levels of calcium flux when used alone.  We hypothesize 
that primary human memory cells are sensitized to releasing calcium stores and 
therefore used a much stronger blockade of calcium signaling.  Specifically, we 
developed a protocol (Ca block) in which we pretreated T cells with the calcium  
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 Fig. 1.9. T Cell ILP Formation is Necessary for Ag Recognition.  (A) Imaging was 
performed as in (Fig. 1.8.A) with additional pretreatment of T cells with latrunculin-A 
before addition to Ag-pulsed EC monolayers. (B) Podo-print/ILP index (average number of 
podo-prints/ILPs per cell) and average calcium flux at 5 min were calculated. Both analyses 
are pooled mean + SEM from from 3 separate experiments. (C) ITmem were labeled with 
Fluo-4 and imaged live with anti-CD3/CD28 cross-linking with or without latrunculin-A 
pretreatment. Left panels show resting T cells. Right panels show activated T cells imaged 
60 seconds after addition of cross-linking antibodies. Arrows indicate de novo formation of 
micron-scale T cell protrusions. (D) Average calcium flux was calculated from three 
separate experiments as in (B). Scale bars represent 5µm. Data represent mean + SEM. 
***p<0.0005. Copyright 2012 The American Association of Immunologist, Inc. 
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chelator BAPTA as well as the CRAC channel inhibitor BTP2, and furthermore used 
imaging buffer with a high (45mM) potassium concentration. On Ag-pulsed ECs, this 
greatly inhibited, but did not completely abolish, calcium flux in iTmem cells, validating 
its use in these experiments.  When we used this calcium blockade on T cells, there was 
a strong reduction in the number of stabilized ILPs demonstrating that calcium flux is 
necessary for ILPs (Fig. 1.10A-C). To determine whether calcium flux was sufficient to 
stabilize ILPs, iTmem were incubated on ECs in the absence of Ag, followed by 
application of the calcium ionophore thapsigargin to directly elevate intracellular 
calcium without any direct TCR signaling present. Addition of thapsigargin resulted in 
robust calcium flux with in seconds.  Moreover, artificially fluxing calcium caused 
iTmem cells already engaged in dynamic ILP probing to arrest ILP turnover and stabilize 
ILP clusters demonstrating that calcium flux is sufficient for ILP stabilization (Fig. 
1.10D-G). Moreover, there was an increase in the number of newly formed ILPs within 
the 120 seconds after addition of thapsigargin. Thus, whereas dynamic ILP probing of 
ECs by iTmem seems to facilitate initial Ag recognition, the resulting rise in calcium is 
both necessary and sufficient to drive formation as well as stabilization of ILPs into 
podo-synapses. 
 
The above findings point to a putative positive feedback loop for sustaining TCR 
signaling. In this loop, the ILPs that facilitate initial TCR signaling and are also 
stabilized by calcium flux downstream of TCR signaling.  To break this loop, we sought 
to block proximal signaling downstream of intracellular calcium flux, specifically  
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 Fig. 1.10. Calcium Flux is Necessary and Sufficient for ILP Stabilization. (A) 
ITmem were Fura-2 labeled, pretreated with the calcium chelator BAPTA and the 
CRAC channel inhibitor BTP-2 and imaged live on Ag pulsed ECs. Arrows 
indicate a few sporadically formed podo-prints. (B and C) Podo-print/ILP index (B) 
and average calcium flux (C) were calculated at 5 min for experiments as in (A). 
(D) Live cell imaging was conducted in the absence of Ag before and after addition 
of the calcium ionophore thapsigargin (at time = ‘0:00’). Arrows indicate 
ILPs/podo-prints. (E) Correlation of calcium flux with ILP number after addition of 
thapsigargin. (F) Quantitation of the number of newly formed ILPs in the 2 minutes 
before and after addition of thapsigargin. (G) Quantitation of the lifetime of ILPs 
with or without addition of thapsigargin. (H and I) Imaging and analysis was 
performed as in A-C except T cells were pretreated with the CAMKII inhbitor 
CK59. Data represent mean + SEM. **p<0.005. ***p<0.0005. Scale bars represent 
5µm. Copyright 2012 The American Association of Immunologist, Inc. 
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targeting calcium-calmodulin dependent kinase II (CAMKII) via the inhibitor CK59 58. 
Blocking CAMKII prevents signaling caused by calcium flux, but does not directly 
block calcium flux itself nor proximal TCR signaling.  Treatment with CK59 attenuated 
Ag-mediated ILP stabilization by ~50% (Fig. 1.10H). This block in ILP stabilization 
was coupled to a proportional decrease calcium flux (Fig. 1.10I). Since CAMKII does 
not block calcium flux directly, the drop in calcium flux in this can possibly be 
attributed to the prevention of ILP formation and as a consequence, inability to find 
additional antigen to sustain signaling.  Collectively, these results strongly support the 
interdependence between ILPs and calcium flux. 
 
CD8 Cytotoxic T Lymphocytes (CTLs) use ILPs to Probe for Ag 
 
The endothelium has been shown to initiate MHC-I/Ag-dependent activation of CD8 
CTL leading to direct killing of endothelial cells 36, 37. To investigate the role of ILPs in 
these responses, previously activated murine OT-I CD8 T cells were incubated on 
murine heart microvascular ECs pulsed with SIINFEKL peptide Ag. Ag-pulsed ECs 
initiated a rapid calcium flux (Fig. 1.11A) that was coupled to progressive specific lysis 
of ECs over a 4 hr duration (~50% lysis ~2 hr; Fig 1.11B). Thus, murine CD8 CTLs can 
respond to antigen presented by murine endothelium.  Live-cell imaging showed that in 
the absence of Ag, CTLs avidly probed the endothelium with dynamic ILPs while 
migrating without any visible calcium flux (Fig. 1.11C). This is the first observation in 
murine studies showing dynamic probing of the endothelium by ILPs looking for sites  
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Fig. 1.11. Murine CD8 CTLs Use ILPs to Sense Ag Bound MHC-I on Endothelium. 
(A) Previously activated murine OTI CD8 T cells (CTLs) were imaged on mem-YFP-
tranfected, mouse heart MVECs pulsed with SIINFEKL. Individual ratiometric calcium 
flux values at 5 min were plotted for -/+ Ag conditions. (B) CTLs were added to mixed 
cultures of Ag-pulsed/unpulsed ECs and percentage of specific lysis is plotted at 
indicated time points. (C) CTLs were imaged during EC probing in the absence of Ag. 
DIC and mem-YFP are shown in the upper and lower panels, respectively. Dashed line 
represents the outline of the migrating CTL under which transient ILPs are continuously 
formed. (D) Imaging was conducted as in (C) on ECs pulsed with SIINFEKL. Red 
arrow indicates initial ILP formation preceding calcium flux. (E) Average offset time 
for calcium flux relative to initial ILP formation. Data represent mean + SEM. Scale 
bars 5µm. Copyright 2012 The American Association of Immunologist, Inc. 
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permissive for transmigration, which mirrors what has been published for human T 
cells. In the presence of Ag, initial ILPs were rapidly followed by calcium flux (offset 
time = 32.8 +/- 6.6 sec), which then lead to migrational arrest and formation of 
peripheral ILP arrays similar to those formed by CD4 effector T cells (Fig. 1.11D, E). 
Thus, T cell ILPs seem to be a general feature of Ag sensing on ECs and not specific 
only to human CD4 T cell models or to superantigen models. 
  
A Planar Coated Cell Model for Ag Recognition 
 
We next considered whether ILPs either represent unique features of T cell-endothelial 
Ag recognition or may be more broadly relevant and uniquely revealed by  
endothelium. Observations with CD4 and CD8 T cells in human and mouse models lead 
us to believe that ILPs may be broadly relevant.  However, we speculated that the 
rigidity of coated substrate models may frustrate/mask ILP formation and 
orientation/resolution issues might obscure detection of ILPs with traditional cellular 
APCs 20 21 24, which may help to explain why ILP probing as a mechanism of TCR 
triggering has not been formally demonstrated previously.   
 
First we simply asked whether evidence for structures consistent with ILPs could be 
detected in a coated glass model (Fig. 1.12A).  Internal Reflection Microscopy (IRM) 
which detects events close in proximity to the imaging plane revealed that initial 
‘micro-contacts’ (~0.2-1 µm dots consistent with T cell ILPs and/or microvilli)  
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 Fig. 1.12. ILPs Facilitate Ag Recognition on Deformable Cell Lines. (A) Schematic of the 
‘Coated-Glass Model’ using ICAM-1- and Ab-coated glass. Inset ‘b’ is a magnified view of the 
interaction surface. (B) iTmem were added to a ICAM-1-Fc- and anti-CD3-coated glass chamber and 
imaged by DIC and IRM. Arrows indicate IRM-detected ‘micro-contacts’. (C) Schematic of the 
‘Planar Coated-Cell APC Model’. CHO-K1 cells expressing ICAM-1-GFP and soluble DsRed 
were surface ‘coated’ with Abs against CD3, CD43 or CD45 using a biotin/streptavidin capture 
approach. Inset ‘d’ is a magnified view of the interaction surface. (D) Cells prepared as in (C) 
coated with anti-CD3 antibody were imaged live upon addition of Fura-2-labeled iTmem. Panels 
demonstrate relatively early and later phases of interaction as indicated. Arrows indicate podo-
prints/ILPs. (E and F) Imaging experiments were conducted as in (D) but T cells were pretreated 
with latrunculin-A. Podo-print/ILP index (E) and calcium flux (F) were calculated. Data represent 
mean + SEM. Scale bars = 5µm. Copyright 2012 The American Association of Immunologist, Inc. 
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preceded calcium flux and new micro-contacts also continued to form after T cell 
spreading (Fig. 1.12B).  We hypothesized that these micro-contacts may at least partly 
reflect ILP activity that was mechanically frustrated by the rigid substrate. To test this 
we designed a ‘Coated-Cell APC’ model whereby the above antibody-coated-glass 
substrate was recapitulated on the surface of a deformable Chinese hamster ovary (Cho-
K1) cell that possesses at least a partial glycocalyx (Fig. 1.12C). In this model, we 
transfected Cho-K1 cells with soluble dsRed and human ICAM-1 conjugated to GFP 
and then coated the surface of the Cho-K1 cells with anti-CD3 using a primary amine 
and biotin-streptavidin approach. In this way, we could detect T cell ILPs by 
topological changes in the surface of the Cho-K1 cells by displacement.   Additionally, 
enforced localization (placement of) of anti-CD3 on the surface of the Cho-K1 cell 
allows us to detect T cell activation as a result of ILP probing of the cell surface.  In this 
setting clear 3-dimensional ILP arrays were readily detected that were coupled to 
calcium flux (Fig. 1.12D). As with iTmem on ECs, initial ILPs always preceded calcium 
flux (Fig. 1.12D; offset time ~56 sec). These ILPs also functionally support calcium 
flux because perturbation of ILP formation using latrunculin-A also completely blocked 
calcium flux (Fig. 1.12E, F). These findings suggest a general tendency of 
memory/effector T cells to employ ILPs to probe diverse substrates for recognition and 
response to Ag. 
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ILPs are Involved in Recognition of Ag Presented by Professional APCs 
 
Next we reexamined Ag recognition with professional APCs.  We considered that, 
although ILP-mediated TCR triggering had not been described before, it may be 
possible that experimental setups were not optimized to visualize ILPs in previous 
studies.  Thus, iTmem were incubated with Preiss B cells pulsed with Ag and imaged by 
confocal microscopy. Imaging ILPs in this manner was difficult because of z plane 
resolution limitations. However imaging of putative ILPs could be seen in occasional 
examples where the T-cells settle on top of B cells such that the IS aligns with the 
optimal imaging plane 23 (Fig. 1.13A).  In these rare examples, structures resembling 
ILPs formed in a ring-shaped arrays around the outside edge between the T cell and B 
cell.  Ultrastructural views, evident in a subset of micrographs, further support the 
presence of T cell ILPs probing the surface of B cells (Fig. 1.13B).  Importantly, the 
ILPs identified within the micrographs have similar morphology as those formed 
between the T cell and endothelium.   
 
Finally, we wanted to determine if ILPs were relevant for dendritic cell presentation of 
specific Ag, which is the most broadly relevant T cell-APC interaction.  Therefore, we 
investigated interaction of murine OTII CD4 T cells incubated with bone marrow 
derived dendritic cells (DCs) co-expressing mem-YFP and soluble DsRed. In this way 
we could identify ILPs that were probing into the surface of the DC much like what we 
had observed on the surface of the endothelium.  Because of the less regular surface of  
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Fig 1.13. ILPs Facilitate Ag Recognition on Professional APCs. (A) ITmem were incubated 
with Ag-pulsed Priess B cells for 5 min and stained for LFA-1 and actin. Image represents a 3-
D projection of T cell settled on top of the B cells with the IS forming more nearly parallel to 
the x-y imaging plane. (B) Transmission electron micrograph of T cell-B cell IS as in (A). The 
T cell is identified by a red overlay. Arrows indicate close intercellular contacts formed by T 
cell ILPs. (C) Schematic (upper left panel) shows both lateral (a) and various ‘en face’ (b) 
interfaces typically formed in vitro between T cells and the highly irregular surfaces of DCs. 
Panels 1 and 2 show previously activated murine CD4 OT-II lymphocytes interacting with Ag-
pulsed mem-YFP-transfected DCs (green, panel 2). Red outlines depict T cell perimeter based 
on DIC imaging (panel 1). Panel 3 is identical to panel 2 but shows three boxed regions (i-iii) 
expanded on the left. 3i shows a lateral interaction in which the T cell has pushed small finger-
like invagination into the side of the BMDC putatively formed by ILPs (arrows). 3ii and 3iii 
show en face interactions whereby ILPs seem to be extending normal to the imaging plane 
giving rise to the typical ring shaped podo-print appearance observed in endothelium (i.e., Fig. 
2). (D) DCs were transfected with sDsRed and mem-YFP, pulsed with Ag and CD4 OT-II T 
cells were added. Panels show cytoplasm displacing podo-prints/ILP (arrows) which precede 
calcium flux and are stabilized after calcium flux. (E) Transmission Electron Micrograph of T 
cell-DC IS as in (D) fixed after 5 min. The T cell is identified by a red overlay. Arrows 
indicate close intercellular contacts formed by T cell ILPs. (F) Calcium flux of previously 
activated CD4 OTII T cells 8 min after interaction with C57BL/6 (WT) or Ciita-/- Ag-pulsed 
DCs with or without latrunculin-A pretreatment. Data represent mean + SEM. Scale bars = 
5µm. Copyright 2012 The American Association of Immunologist, Inc. 
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DCs compared to ECs, T cells interacted with DCs both laterally (Fig. 1.13C, ‘a’ 
subset) and to a lesser extent through en face contacts (Fig. 1.13C ‘b’ subset). In the 
former, side views of DC invaginations were readily evident that were similar to podo-
prints/ILPs seen on endothelium (Fig. 1.13C, 3i). En face interactions also revealed 
discrete circular podo-prints/ILPs (Fig. 1.13C, 3ii, 3iii), though these were generally 
less obvious than those formed on endothelium due to the highly active and irregular 
surface topology of DCs. Dynamic imaging showed that when the DCs were pulsed 
with antigen (OVA 323-339), ILP probing preceded calcium flux, which in turn was 
coupled to peripheral ILP array formation similarly to ILP arrays formed on ECs (Fig. 
1.13D). Ultrastructural confirmation of ILP formation could also be obtained in a subset 
of electron micrographs (Fig. 1.13E). Finally, treatment of T cells with latrunculin-A 
strongly inhibited ILPs (data not shown) and completely blocked initial calcium 
responses to Ag presented by DCs (Fig. 1.13F). Therefore, T cell probing for antigen by 
ILPs occurs when they are interacting with surfaces of both professional APCs as well 
as other diverse cell surfaces, a finding which until now had been difficult to identify 
due to suboptimal assay conditions. 
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DISCUSSION 
 
We find that human CD4 T memory cells use ILPs to probe the surface of antigen 
presenting cells to find cognate antigen.  These ILPs not only are responsible for 
overcoming the steric and electrostatic barriers that prevent TCR-MHC binding, but 
also are important in the stabilization of signaling.  Perturbation of ILPs led to almost 
complete abolishment of antigen-dependent calcium flux.  Moreover, ILP 
stabilization required calcium flux, forming a positive feedback loop necessary for 
prolonged signaling.  These studies are not only applicable to human CD4 T cells, as 
studies with murine CD4 and CD8 cells in a number of APC models show strikingly 
similar phenomenon.   
 
Vascular ECs represent intriguing and understudied APCs/target cells for adaptive 
immune responses. These MHC-I-, MHC-II- and co-stimulator-expressing cells are 
strategically positioned at the blood-tissue interface to serve as unique sentinels for 
the immune system 31. Previous studies demonstrated that ECs can effectively re-
stimulate memory/effector, but not naïve, T cells because they generally lack 
expression of B7-1 and B7-2 31 32 33 35 36 59 38. Thus, ECs have been hypothesized to 
serve as peripheral ancillary or ‘semi-professional’ APCs that contribute to the 
effector phase of adaptive immune responses by activating memory cells. Though 
overall roles remain controversial, studies suggest that Ag presentation by ECs can 
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influence T cell activation, differentiation, trafficking and memory 31 32 33 60. In our 
current study we demonstrate that CD4 and CD8 memory/effector T cells exhibited a 
transient arrest in migration coupled, respectively, to activation on ECs presenting 
MHC/Ag, consistent with previous findings 36 61 62.   
 
We hypothesize that while T cells are probing the surface of the endothelium with 
ILPs searching for sites permissive for transmigration, they are interacting with 
immune receptors.  Therefore, if antigen is being presented by the endothelium, the 
T cell would recognize its antigen and become activated.  The benefit to this process 
would be that the T cell would be primed before entering the tissue and would have a 
quicker and more robust response.  For instance, if the endothelium has been 
exposed to a virus, viral antigens presented on the surface could prime CD8 CTLs 
undergoing transendothelial migration.  Then, the CD8 CTLs would be able to kill 
the virally infected endothelial cell as well as start producing cytokines so that 
subsequent killing of virally infected cells in the tissue would be more efficient.  
 
Moreover, since the endothelium can express PD-L1 and other inhibitory molecules, 
the endothelium may be instrumental in resolving tissue inflammation or preventing 
autoimmunity.  Thus, the endothelium may serve as sentinels of the tissue and can 
cause functional inactivation of effector cells before they can encounter sensitive 
tissues.  In support of this, it has been shown that in vitro blockade of PD-L1 
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enhances the ability of human CD8 T cells to kill endothelial cells and this blockade 
further enhances the ability of the CD8 cells to produce IFNγ63. Unfortunately, 
genetic models are lacking to study the role of the vascular endothelium in adaptive 
immunity in vivo, so it is still unclear what role endothelial antigen presentation fills 
in a physiological setting. The lack of proper in vivo models is due largely to 
“leakiness” of endothelial promoters used to drive Cre recombination for the 
necessary endothelial-specific conditional knockout strains. For instance, the Tie-
2:Cre mouse deletes not only on the endothelium but also on professional APCs such 
as B cells and DCs 64 65. This is due to the fact that both endothelial and 
hematopoietic cells derive from the same developmental precursor termed the 
hemagioblast66.  Only through specific conditional deletion of antigen presentation 
components/costimulatory molecules specifically on the endothelium will the exact 
role of the endothelium in antigen presentation be clearly delineated. 
 
Importantly, ECs exhibit a virtually planar cell surface in vitro, which we previously 
established to be ideal for high spatiotemporal resolution imaging of topological 
dynamics 39. We reasoned that ECs might, therefore, serve as physiologic ‘planar 
APC/target cell’ models uniquely suited to fill two key gaps in our understanding of 
immune surveillance mechanisms: i) how initial MHC/Ag-sampling contacts form 
between T cells and APCs and ii) how these lead to formation of productive ISs. 
Whereas planar APC substrates (i.e., lipid bilayers, antibody-coated glass) provide 
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excellent imaging, which has led to critical insights to these responses 18 24 25 26 27, 
such models are inherently limiting. Additionally, details of physiologic cell-cell 
scanning dynamics are profoundly obscured by orientation-related imaging issues 20 
21 23. The imaging afforded with our planar endothelial APC model in the current 
study revealed unexpected involvement of ILPs in Ag recognition and response 
activities.   
 
ILPs (‘invadosome-like protrusions’) are lymphocyte equivalents 42 to podosomes 
(formed largely by myeloid lineage cells) and invadopodia (formed by transformed 
cells), collectively termed ‘invadosomes’ 41. Invadosomes and ILPs are actin-
dependent cylindrical protrusive organelles (~200-1000 nm in diameter and depth) 
that form on the ventral surface of migratory cells 41. Distinct from invadosomes, 
characterized to form on matrix, bone, glass/plastic substrates, T cell ILPs have only 
been seen on cellular substrates, as shown in a range of in vitro 39 67 68 and in vivo 
studies (reviewed in 4). In such settings, dynamic ILP probing seems to function in 
migratory pathfinding, apparently serving as biomechanical sensors 39 67 68 69. The 
current studies suggest that ILPs may also facilitate biochemical or ‘informational’ 
scanning of diverse cell surfaces (Fig. 1.14).  This informational scanning may not 
be limited to scanning for antigen.  We hypothesize that this scanning is important 
for recognition of other immune receptors and also for search for chemokines that 
are trapped within the glycocalyx.  
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Fig. 1.14. Hypothetical Model for ILP Function in Ag Recognition and Response 
Schematic depicts top-down and side views of a memory/effector T cell interacting with 
an APC/target cell. Lymphocytes initiate lateral migration (Step 1) and begin to 
dynamically drive ILPs against the apposing cell (Step 2, inset 2a). Close interactions 
between T and APC/target cells, which are partially opposed by the cell glycocalyces 
(inset 2b), form preferentially (but not exclusively) at ILP tips (insets 2c). We 
hypothesize that TCR/MHC interactions may be facilitated in these zones. Initial calcium 
released upon Ag recognition (green overlay/arrows; Step 3) seems to be coupled to 
stabilization/accumulation of ILP arrays (‘podo-synapses’; Step 4), which we hypothesize 
could in turn help sustain/enhance signaling (Step 5). Copyright 2012 The American 
Association of Immunologist, Inc. 
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We speculated that the ILP scanning seen on ECs was uniquely revealed by this 
setting, rather than a unique feature of it. IRM imaging of a rudimentary APC model 
(anti-CD3-coated glass) showed that T cells form a series of micro-contacts with the 
substrate that are consistent with either ILP or microvilli interactions. Similar micro-
contacts were previously shown to be enriched in F-actin, WASP and TCR and 
hypothesized to represent frustrated podosomes 25 27. When we tested this hypothesis 
by recapitulating the same anti-CD3 activation stimuli on a pliable cell surface we, 
indeed, found that the micro-contacts transitioned into 3D ILPs and podo-prints. 
Moreover, our studies using approaches optimized for imaging ILPs on professional 
APCs (i.e., B cells and DCs) readily detected ILPs probing in these settings. We 
believe that our specific experimental design uniquely allowed us to detect ILPs that 
are generally present during immune surveillance though not detected in previous 
studies. Although dynamics, molecular composition and 3D-architectures were not 
defined, extensive (largely EM-based) studies previously evidenced similar T cell 
protrusions extending against diverse APCs and target cell surfaces 26 51 70 71 72 73. 
Collectively, this suggests broad relevance for memory/effector T cells probing their 
cellular environment with ILPs.  
 
 
The important question of whether naïve T cells similarly employ ILPs remains to be 
addressed.  We were unable to determine if naïve cells interacting on endothelium 
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were able to form ILP structures because naïve cells lack the requisite levels of LFA-
1 or responsiveness to inflammatory chemokines to efficiently interact with activated 
endothelium. Moreover, when we assessed naïve cells on professional APCs, such as 
dendritic cells, we found some minor evidence of ILP structures, however there was 
little calcium flux and ILP stabilization in these settings. We believe that the reason 
for this is that naïve T cells need to have periods of short interaction with 
professional APCs in a priming step before full calcium flux can be achieved, which 
has been demonstrated in vivo by intravital microscopy74. Because we could not 
measure significant ILPs being formed by naïve cells, and we did not see meaningful 
calcium flux, we believe that ILPs may still be responsible for activation of naïve T 
cells, but that the kinetics are delayed beyond the imaging window of our 
experiments. However, future experimental setups can be designed to test this 
directly. 
 
One possible role for ILP probing may be in enhancing the efficiency of Ag 
recognition. The act of Ag detection requires T cell and APC/target membranes to 
come within ~14 nm of each other 5 75. Yet all cell membranes are extensively 
shielded by ~50-500 nm thick glycocalyxes 6 7 8 that physically oppose close contact 
and negatively modulate immune recognition 8 9 10 11 12 13 (Fig. 1.14, inset 2b). In the 
periphery, patrolling effector/memory lymphocytes must effectively scan the 
surfaces of widely varying cell types (indeed, essentially any host cell could become 
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a target), each with glycocalyxes of different thicknesses and physico-chemical 
properties. Forces provided by ILPs (which form independently of Ag during lateral 
migration 39) are sufficient to deform nuclear lamina, displace and distort 
cytoskeleton and intracellular organelles and to promote trans-cellular diapedesis 39. 
More than sufficient energy would, therefore, seem to be available at the tips of ILPs 
(Fig. 1.14, inset 2a) to overcome repulsion provided by the glycocalyx and to 
provide the force required for TCR triggering (Fig. 1.14, inset 2c). 
 
Previous studies showed that lamellipodia of migrating lymphocytes are zones of 
heightened Ag recognition efficiency 76 77 78. In both our previous 39 and current 
work we show that lamellipodia are also the predominant areas of ILP formation. 
Moreover, in our experimental system ILPs, but not necessarily lamellipodia, 
consistently preceded calcium flux. Thus, while migration behaviors are necessary 
for immune surveillance, ILPs may function more directly in promoting intimate 
contacts and, thereby ensuring efficient Ag sampling. Our studies with Latrunculin A 
are consistent with such functional roles. It is also interesting to note that forces and 
membrane bending associated with ILPs are consistent with the hypothesized force-
based mechanism for formal triggering of TCR signaling 27 79.  Here we used CD3 
crosslinking as an approximate control for TCR signaling that is not dependent on 
ILPs.  Yet, when we added the actin perturbation agent Latrunculin-A we detected 
less calcium flux. Although some studies have interpreted this to indicate that 
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Latrunculin-A blocks TCR signaling independently of its function in blocking actin, 
we believe that even CD3 crosslinking in this setting is facilitated, at least in some 
part, by forces generated by ILPs.  ILPs are probably not absolutely required for 
either TCR signaling or forming intimate T cell-APC/target contacts, but rather act to 
ensure efficiency and fidelity of immune surveillance. It is also probable that the 
curvature and membrane bending elicited by ILPs may also allow immune receptors 
to assemble in the correct arrangement of molecules to form a proper immune 
synapse, which is the at the center of the kinetic segregation model.  
 
Another possible function for ILPs may be to support signal amplification and 
sustenance. Our studies reveal dense arrays of calcium-stabilized ILPs that dominate 
the IS following Ag recognition. Individual ILPs showed enrichment in TCR and 
molecules suggestive of active signaling. This feature is generally not unlike TCR 
signaling micro-clusters defined using planar APC model substrates, with the key 
distinction that ILPs have a discrete 3D architecture, do not “treadmill” across the T 
cell interface, and ultimately do not end up forming a c-SMAC architecture.  The 
well developed concept that micro-clusters may function as ‘signalosomes’ to 
amplify and sustain signaling by concentrating important molecules/activities, might 
then be extended to include limited ‘reaction volumes’ formed within ILPs 21 80 81 82.   
Therefore, the tips of ILPs may, in fact, be types of microclusters that are potent 
locations for signaling.  Additionally, stable peripheral ILP arrays are strikingly 
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similar to osteoclast ‘podosome-belts’ 83 84 that form sealing zones for directed 
secretion of bone degrading enzymes 85. Thus, it may be hypothesized that peripheral 
podo-synapses may function analogously for directed secretion of cytokines or 
cytotoxic materials.  For instance, podosynapses would enable a CD8 CTL that is 
killing a target cell to specifically lyse the virally infected cell while leaving 
bystander cells unharmed.  Staining of perforin or granzyme within the ILPs would 
help to delineate this possibility.   
 
Collectively, these studies support the hypothesis that ILPs may serve as newly 
appreciated sensory organelles that facilitate Ag recognition and responses. By virtue 
of physical force exertion, ILPs allow T cells to get a deeper understanding of their 
local cellular environment. Such proactive ‘informational scanning’ might ensure 
robust sampling of MHC/Ag on diverse cell types. It is tempting to speculate that 
stabilized TCR-enriched ILPs resulting from Ag recognition represent a clearer, 
more physiologic, view of TCR-micro-clusters and ‘multi-focal’ ISs than what is 
characterized to date. 
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Chapter 2. The role of PD-1 in controlling Lymph Node and Blood T Follicular 
Regulatory Cells 
 
Note: The contents of this project have been published previously 86. 
 
Introduction 
 
Humoral immunity refers to B cells in the body being activated to produce soluble 
antibodies that protect the host from foreign pathogens.  The antibodies produced by 
the B cell have multiple functions including directly neutralizing toxins, aiding in 
opsonization, triggering activation through Fc receptors on multiple cell types and 
coating pathogens that get killed by antigen dependent cell cytotoxicity (ADCC).  
For many years it has been appreciated that CD4 T cells are essential mediators of 
humoral immunity.  In fact, humoral respones have traditionally been categorized as 
either T cell dependent or T cell independent.  It is clear that the vast majority of 
humoral responses are CD4 T cell dependent, and CD4 T cells are critical in 
providing help to B cells in these situations87.  However, for many years, the CD4 T 
cells that supply this help to B cells could not be phenotypically or functionally 
separated from T cells that stay in the T cell zone and perform other functions.  
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T Follicular helper T cells (TFH) are a recently defined subset of CD4 T cells that are 
essential for helping cognate B cells form and maintain the germinal center (GC) 
reaction, and for development of humoral immune responses. Tfh cells were first 
appreciated 12 years ago when the Forster and Moser labs simultaneously isolated 
tonsilar human CD4 T cells that express the chemokine receptor CXCR588 89.  These 
cells were shown to have the unique ability to stimulate B cells to produce antibody 
in vitro and were physically located within B cell zones in vivo.  
 
TFH cells are universally defined by expression of CXCR5, which is responsible for 
directing them to the B cell follicles.  Within the B cell follicles follicular dendritic 
(FDCs) cells secrete large amounts of the chemokine CXCL13 which allows B cells 
and T cell subsets to enter the follicle if there is sufficient CXCR5 expressed on the 
surface of these cells 90. Germinal centers, where affinity maturation and class switch 
recombination take place, are locations where there is a particularly high 
concentration of CXCL13.  B cells constitutively express CXCR5, which places 
them in the B cell zone in the steady state.  When B cells become activated, they can 
upregulate CCR7 and migrate to the T-B border91.  In contrast, T cell subsets, such 
as TFH cells, only express CXCR5 after differentiation and activation. It is thought 
that dendritic cells prime naïve T cells to become TFH cells, however B cells at the 
T-B border may also function in this capacity.  Moreover, it is generally thought that 
B cells provide important costimulatory cues through ICOS and SAP that lead to 
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stabilization of the TFH phenotype 92 93.  Until recently, it was thought that TFH cells 
are the only CD4 T cell subtype that was able to gain entry into the B cell zone and 
germinal center to regulate B cell responses.  
 
TFH cells express the transcription factor Bcl6 (which represses Blimp-1/Prdm1) and 
high levels of the costimulatory receptor ICOS, which are both critical for TFH 
differentiation and maintenance 90, 94-96. In this way, Bcl6 is thought to be the master 
transcription factor for TFH differentiation, much like RORγT is for Th17 
differentiation.  In addition, TFH cells secrete large amounts of IL-21, which aids in 
germinal center formation, isotype switching and plasma cell formation 97.  It has 
been demonstrated previously that mice deficient in IL-21 have severely impaired 
antibody responses97.  In humans and mice, functionally similar TFH cells can be 
found in secondary lymphoid organs. Significantly, CXCR5+ TFH cells are also 
present in peripheral blood and are seen at elevated levels in individuals with 
autoantibodies, including systemic lupus erythematosis, myasthenia gravis and 
juvenile dermatomyositis patients.  However, the function of these circulating TFH 
remains unclear, because most data has relied on in vitro models 88, 98-100. 
 
TFH cells also express high levels of programmed death (PD)-1 receptor (CD279). 
PD-1 was originally cloned from a T cell hybridoma undergoing apoptosis after 
exposure to PMA and ionomycin101. PD-1 is an Ig superfamily member that has one 
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N-terminal IgV-like domain.   The cytoplasmic tail of PD-1 has an immunoreceptor 
tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine-based 
switch motif (ITSM) 2.  It is currently believed that recruitment of SHP2 via the 
ITSM domain102 during PD-1 signaling attenuates TCR signals and inhibits T cell 
expansion, cytokine production and cytolytic function (Fig. 2.1). In addition, PD-1 
promotes the development of induced regulatory T (iTreg) cells from naïve 
lymphocytes 103-107.  
 
PD-1 has two ligands, PD-L1 (B7-H1;CD274) 108 and PD-L2 (B7-DC; CD273) 109.   
PD-L1 is constituitively expressed on many hematopoietic cells such as B cells, T 
cells, macrophages, dendritic cells, mast cells and endothelial cells and expression 
can be induced to even higher levels on these cells as well as wide variety of 
nonhematopoietic cells including pancreatic islet cells. Thus, PD-L1 is broadly 
expressed in many tissues. PD-L1 has a 27 amino acid cytoplasmic domain that is 
highly conserved across species, yet has no known signaling domain.  PD-L2 is 
inducibly expressed by hematopoietic cells such as B cells and dendritic cells and 
has no significant cytoplasmic tail. Importantly, both PD-L1 and PD-L2 can be 
expressed on GC B cells and dendritic cells, making both ligands potentially 
important for humoral immune responses 2.  
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Fig. 2.1.  PD-1 Signaling.  Studies of PD-1 signaling suggest that binding of the ITSM motif by SHP-2 
results in the dephosphorylation of proximal TCR signaling molecules and augmentation of PTEN 
expression.  Together these result in attenuation of the PI3K pathway.  Taken from2. 
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Perturbation studies suggest critical roles for PD-1 pathway in regulating humoral 
immune responses.  However, there are conflicting reports as to the function of the 
PD-1 pathway in controlling humoral immunity. Some studies have found that 
humoral responses are attenuated 110-112, while others have seen that humoral 
responses are heightened 113, 114 when PD-1:PD-L interactions are prevented. This 
may be due to the complexity of the signaling in the PD-1 pathway, as multiple cell 
types express PD-1, PD-L1 and PD-L2. Therefore, it is still uncertain how PD-1 
influences humoral immunity and moreover, what cellular interactions are affected 
by PD-1 to regulate humoral immunity responses. 
 
PD-1 also is found on a newly defined subset of CD4+CXCR5+ cells called T 
follicular regulatory (TFR) cells.  TFR cells were discovered simultaneously by the 
Dong and Vinuesa groups in 2011, and since then only one other paper has been 
published on this cell type.  Therefore, we only have a rudimentary understanding of 
these cells.  We know that TFR cells are positive for the transcription factors FoxP3, 
Bcl6 and Prdm1/Blimp1.  Coexpression of Bcl6 and Blimp1 is paradoxical as these 
transcription factors have been shown to reciprocally modulate eachother in TFH cell 
differentiation.  TFR cells are thought to function in inhibiting the germinal center 
response 115-117.  However, this hypothesis is based on the observation that these cells 
have FoxP3 expression, and clear direct evidence of the suppressive nature of the 
cells is currently lacking. Some genetic models have indirectly demonstrated the 
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suppressive nature of TFR cells but these models rely on manipulations that do not 
only alter the function of TFR cells115 116.  For example, Chung et al. transferred 
CXCR5 knockout Treg cells into and then immunized recipient mice.  The mice that 
received CXCR5 knockout Treg cells suppressed germinal center B cell 
development less than wild-type T regulatory cells.  However, the regulatory cells 
that came from the CXCR5 knockout mouse may have been defective from 
differentiating in an altered lymph node architecture 116. Additionally, these studies 
do not separate differentiation from function.  Therefore, it is still unclear what the 
role of TFR cells are in inhibiting humoral immunity.  Interestingly, TFR cells 
originate from natural regulatory T cell (nTreg) cells115, 116, which makes them one of 
the only defined effector subsets of nTregs to date118. 
 
Although they originate from nTregs, TFR cells express similar levels of ICOS, 
CXCR5 and PD-1 as TFH cells, which prevented these cells from being detected until 
recently.  Thus, TFR cells have been “hiding” in TFH gating strategies all along. Since 
ICOS, CXCR5 and PD-1 have been widely used to identify and purify ‘TFH cells’, it 
seems likely that the inability to define clear functions for PD-1 in GC responses 
derives from experimental systems containing mixtures of stimulatory TFH cells and 
inhibitory TFR cells. Separate analyses of the function of PD-1 on TFH and TFR cells 
are needed to elucidate how PD-1 controls humoral immunity and to gain insight into 
the individual roles of TFR cells and TFH cells in regulating antibody production. 
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Here we demonstrate that PD-1:PD-L1 interactions inhibit TFR, but not TFH, cell 
numbers in lymph nodes. PD-1 deficient mice have increased numbers of lymph 
node TFR cells compared to wild type mice. PD-1 deficient lymph node TFR cells 
have enhanced ability to suppress activation of naïve T cells, as well as antibody 
production in vitro. In addition, we show for the first time that TFR cells are present 
in the peripheral blood of mice, and that these circulating cells can potently regulate 
humoral immune responses in vivo.  Using transfer approaches, we demonstrate that 
blood TFH cells can promote antibody production, while blood TFR cells can strongly 
inhibit antibody production in vivo. We further show that the PD-1 pathway inhibits 
blood TFR cell function and PD-1 deficient blood TFR cells have enhanced 
suppressive capacity in vivo. Taken together, our studies reveal a new 
immunoregulatory role for the PD-1:PD-L1 pathway in limiting TFR cell 
differentiation and function, and further demonstrate the dynamic control of humoral 
immune responses by migration of TFR cells from the circulation into lymph nodes 
to control antibody production in vivo. 
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Materials and Methods 
Mice.  6-10 week old mice were used for all experiments.  WT C57BL/6 and TCRα-
/- mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  PD-1-/-
(Pdcd1-/-), PD-L1-/- (Cd274–/–), and PD-L2-/- (Pdcd1lg2–/–) mice on the C57BL/6 
background were generated in our laboratory 119-121.  Icos-/- 122 and Cd28-/- mice 123 
were generated as described. 2D2 TCR Tg mice Foxp3-IRES-GFP knockin mice 
(Foxp3.GFP; 124 were generated in our laboratory by crossing 2D2 TCR Tg mice 125 
with Foxp3.GFP reporter mice. All mice were used according to the Harvard 
Medical School Standing Committee on Animals and National Institutes of Health 
animal healthcare guidelines.  Animal protocols were approved by the Harvard 
Medical School Standing Committee on Animals.   
 
Immunizations.  For MOG 35-55 immunizations (referred to as “MOG”), mice 
were injected subcutaneously with 100µg of MOG 35-55 (UCLA Biopolymers 
Facility) emulsified in a 1:1 emulsion of Mycobacterium tuberculosis H37RA CFA 
(Sigma) on the mouse flanks.  Emulsions were made by mixing MOG in PBS and 
pulling the mixture into a syringe.  A separate syringe was filled with CFA and the 
two syringes were joined with a 3-way stopcock and mixed until a uniform, thick 
suspension was generated that did not dissolve in PBS. 100µl of emulsion was 
injected in two places on the mouse flanks in an optimal location so that the inguinal 
lymph node is the primary draining lymph node for the immunization.  Seven days 
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after immunization mice were euthanized and the inguinal, and therefore, draining 
lymph nodes (dLNs) and/or spleen were harvested for flow cytometric analyses.  
Blood was collected via cardiac puncture with a 1cc syringe and immune cells were 
isolated by sucrose density centrifugation using Lymphocyte Separation Media 
(LSM).  For NP-OVA immunizations, 100µg NP18-OVA (Biosearch Technologies) 
was used in a 1:1 H37RA CFA emulsion and injected similarly as MOG/CFA. 
 
ELISA.  For in vitro quantification of antibody production, supernatants were taken 
from cultures and incubated on plates that were coated with 1:1000 dilution of pan-
IgG capture antibody (Southern Biotech) overnight at 4 degrees. Samples were 
diluted and added to plates for 1 hour at room temperature.  Plates were washed and 
1:1000 of alkaline phosphatase conjugated pan-IgG detection antibody (Southern 
Biotech) was added for 1 hour.  A phosphatase substrate (Sigma) was used to 
quantiate antibody titers.  
 
To assess in vivo antibody production, sera were collected from mice at indicated 
time points by centrifugation in serum separator tubes.  NP-specific antibody titers 
were measured by coating ELISA plates with 100µg/ml NP16-BSA (Biosearch 
Technologies) in PBS overnight at 4 degrees, and incubating serum for 1hr followed 
by alkaline phosphatase-conjugated IgG detection antibodies.  A standard curve was 
generated using antibody from an NP-specific IgG1 hybridoma (a kind gift of Dr. 
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Michael Carroll).  This standard curve was used to approximate all IgG subtype 
antibody levels in the linear range of detection using a Spectramax Elisa plate reader 
(Molecular Devices).   
 
Flow Cytometry.  Cells from lymphoid organs were isolated and resuspended in 
staining buffer (PBS containing 1% fetal calf serum and 2mM EDTA) and stained 
with directly labeled antibodies from Biolegend against CD4 (RM4-5), ICOS (15F9), 
CD19 (6D5), PD-1 (RMP1-30), PD-L1 (10F.9G2), CD69 (H1.2F3), from 
eBioscience against FoxP3 (FJK-16S), Bcl6 (mGI191E), and from BD bioscience 
against FAS (Jo2), GL7, Ki67 (B56). For CXCR5 staining, biotinylated anti-CXCR5 
(2G8, BD Biosciences) was used followed by streptavidin-brilliant violet 421 
(Biolegend).  For intracellular staining, the FoxP3 fix/perm kit was used 
(eBioscience) after surface staining was accomplished. All flow cytometry was 
analyzed with an LSR II (BD biosciences) using standard filter sets.  
 
Confocal Microscopy.  Draining lymph nodes were embedded in OCT which were 
frozen quickly with liquid nitrogen and 8µm sections were cut on a cryostat, fixed 
with 4% paraformaldehyde, and stained before imaging on a Zeiss LSM 510 
confocal microscope by acquiring z-stacks of 0.5µm with a 40x oil objective.  
Germinal center quantitation was calculated by drawing outlines around GL7+IgD– 
areas present within the B cell zone.  FoxP3 quantitation was performed by 
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determining germinal center zones and scrolling through z-stack images to identify 
large FoxP3 positive spots. Axiovision (Zeiss) software was used to measure 
distances from germinal center borders.  For micrograph panels, single z slices were 
linearly contrasted and merged images were made in Adobe photoshop.  In some 
cases digital enlargements were made with Adobe photoshop.   
 
Quantitative PCR.   RNA was isolated from sorted samples with the RNAqueous 
micro RNA extraction kit (Ambion) according to manufacturers instructions.  Q-
PCR was performed using standard FAM or VIC conjugated TaqMAN probes 
(Applied Biosystems) and an ABI FAST9500 QPCR machine according to the 
manufacturer’s instructions.  mRNA levels were normalized to HPRT or β2M, and 
the 2-deltadeltaCT method was used to quantitate mRNA. Each bar graph represents 
mean values from more than three individual experiments consisting of cells sorted 
from 10 pooled mice.  Samples were normalized to wild-type naïve cells as 
described in the figure legends.   
 
In vitro Suppression Assay.  Cell populations were sorted to 99% purity on an Aria 
II flow cytometer using a 70 micron nozzle.  For TFR suppression assays, sorted cells 
were counted on an Accuri cytometer (BD biosciences) by gating live cells only.  
1x105 GL7- B cells from dLNs of WT mice immunized with MOG/CFA 7 days 
previously, 1x105 CFSE labeled CD4+CD62L+FoxP3- T responder cells from 
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unimmunized WT FoxP3 GFP reporter mice, and 1x105 TFR cells from the draining 
dLN of 10 pooled mice immunized with MOG/CFA 7 days previously were plated 
with 2µg/ml soluble anti-CD3 (2C11, BioXcell) and 5µg/ml anti-IgM (Jackson 
Immunoresearch).  After 3 days, cells were harvested and stained for CD4 and 
CD19.  T cell responders were identified as CFSE positive, and percent divided was 
gated as the percent of cells with CFSE diluted compared to unstimulated T 
responders. For in vitro antibody suppression assay, GL7– B cells from wild-type 
MOG-immunized mice were plated with TFH cells and/or TFR cells pooled from 
MOG-immunized wild-type or Pdcd1–/– mice and 2µg/ml soluble anti-CD3 and anti-
IgM (as described above).  After 6 days, supernatants were collected for antibody 
analysis by enzyme-linked immunosorbent assay.   
 
Adoptive Transfers.  For blood TFH/TFR adoptive transfers, 20 to 30 WT mice were 
immunized with NP-OVA subcutaneously as described above, and 8 days later blood 
was collected by cardiac puncture. TFH and TFR cells were sorted as described 
above.  4x104 blood TFH cells alone or together with 2x104 blood TFR cells in 100µl 
PBS were adoptively transferred into CD28-/- or TCRα-/- mice by tail vein injection.  
These recipient mice were immunized with NP-OVA one day later on the flanks as 
described above.  Sera and organs were harvested at indicated times and analyzed by 
ELISA or flow cytometry.       
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Statistical Analysis.  Unpaired Student’s t test was used for all comparisons, data 
represented as mean +/- SD or SE are shown.  P values < 0.05 were considered 
statistically significant. * P<0.05, ** P<0.005, *** P<0.0005.   
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Results 
PD-1 Controls T Follicular Regulatory Cells 
 
To analyze the role of PD-1 in controlling T follicular regulatory (TFR) cells, we first 
compared PD-1 expression on CD4 T cell subsets in draining lymph nodes (dLN) of 
WT C57BL/6 mice subcutaneously immunized with myelin oligodendrocyte 
glycoprotein (MOG) peptide 35-55 emulsified in CFA (from hereon simply referred 
to as “MOG/CFA”), an immunization that breaks tolerance and also results in 
effective TFH cell generation 126. TFR cells were defined as 
CD4+ICOS+CXCR5+FoxP3+CD19-, a gating strategy that separates TFR cells from 
CD4+ICOS+CXCR5+FoxP3-CD19- TFH cells, the cell type that was until recently 
thought to solely comprise the CD4+CXCR5+ gate (Fig. 2.2A). TFH cells showed 
higher expression of PD-1 compared to ICOS+CXCR5- effector-like cells and ICOS-
CXCR5- naïve (referred to as naïve) cells in the draining lymph node on day 7 after 
immunization. Strikingly, TFR cells had even higher PD-1 expression when 
compared to the other CD4 T cell subsets examined, including TFH cells (Fig. 2.2B). 
 
To determine the functional significance of PD-1 expression on TFR cells, we 
immunized WT and Pdcd1-/- (PD-1-/-) mice and analyzed TFR cells 7 days later. The 
percentage of TFR cells contained within the CD4+FoxP3+ gate was about 4 percent 
in WT lymph nodes and less than 1 percent of all CD4 T cells. In marked contrast,  
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 Fig. 2.2.  PD-1 Signaling in FoxP3 Tregs Limits the Generation of T Follicular 
Regulatory Cells.  (A) Quantitation of TFR cells.  WT mice were immunized with 
MOG/CFA and 7 days later draining lymph nodes were isolated and immediately stained for 
CD4+FoxP3+ICOS+CXCR5+CD19- T follicular regulatory cells (TFR), CD4+FoxP3-
ICOS+CXCR5+CD19- T follicular helper cells (TFH), CD4+ICOS-CXCR5-CD19- cells 
(naive) or CD4+ICOS+CXCR5-CD19- cells (ICOS+).  Numbers indicate percentages of cells 
located within each gate. (B) PD-1 expression by flow cytometry on WT naive, ICOS+, TFR 
and TFH cells.  Populations were gated as in (A). (C) Gating of TFR cells from total FoxP3+ 
cells in WT and PD-1-/- mice immunized with MOG/CFA and analyzed 7 days later and 
stained as in (A).  (D) Quantitation of WT or PD-1-/- TFR cells gated in (C) and expressed as 
a percentage of CD4+FoxP3+ (left), percentage of total CD4 T cells (middle), or percentage 
of CD4+ICOS+CXCR5+CD19- gate (right). (E) Quantitation of TFH cells as a percentage of 
total CD4 T cells.  Data represent means of 5 mice per group. All error bars indicate 
standard error. (F) PD-1 on FoxP3+ cells has a cell-intrinsic role in inhibiting TFR 
differentiation in vivo. Schematic design of a transfer assay in which 2D2 TCR transgenic 
CD4+FoxP3+CXCR5- non-TFR Tregs were transferred into WT mice which were 
subsequently immunized with MOG/CFA. Draining lymph nodes were harvested 7 days 
later and analyzed for TFR cells.  (G) Representative gating of TFR cells from transfer 
experiments described in (F).  (H-I) Quantitation of TFR cells from transfer experiments 
expressed as a percentage of FoxP3 GFP+ cells present on day 7 post immunization (H) or 
total cell number (J) per lymph node. All data are representative of at least two independent 
experiments with at least 5 mice per group.  All error bars indicate standard error. * P<0.05, 
** P<0.005 
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the percentage of TFR cells in Pdcd1-/- mice was about 10 percent of the 
CD4+FoxP3+ gate and greater than 2 percent of all CD4 T cells (Fig. 2.2C-D). 
Because total numbers of CD4 T cells are typically about two fold higher in the 
lymph nodes of PD-1 deficient animals, a two-fold increase in TFR cell frequency 
translates into a ~4-fold increase in absolute numbers of TFR cells (data not shown). 
When expressed as a percentage of all CD4+ICOS+CXCR5+ cells (and therefore the 
percentage of CD4 T cells that respond to CXCL13 and can migrate to the B cell 
zone), Pdcd1-/- TFR cells comprised half of this population, whereas WT TFR cells 
comprised only about 20 percent (Fig. 2.2D). The dramatic increase in the 
percentage of TFR cells in Pdcd1-/- mice also was observed when other classical B 
cell antigens, such as 4-hydroxy-3-nitrophenylacetyl hapten conjugated to ovalbumin 
(NP-OVA), were used (Fig. 2.3). We did not find a significant difference in the 
percentage of FoxP3- TFH (from hereon called “TFH”) cells when expressed as a 
percentage of all CD4 T cells in WT and Pdcd1-/- mice on day 7 post immunization 
(Fig. 2.2E).  
 
Since PD-1 can be expressed by a number of hematopoietic cell types including T 
cells, B cells, macrophages and some dendritic cells 2, we next investigated whether 
PD-1 regulates TFR cells directly by controlling their generation from FoxP3+ T 
regulatory cells (Treg). To track the fate of FoxP3+ cells following transfer into WT 
mouse recipients, we used antigen-specific FoxP3+ T cells from TCR transgenic  
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Fig. 2.3.  PD-1 Signaling Limits the Generation of T Follicular 
Regulatory Cells in response to NP-OVA Immunization.  (A) Gating of 
TFH and TFR cells from WT and Pdcd1-/- mice immunized with NP-OVA 
in CFA and analyzed 7 days later.  (B) Quantification n of WT or PD-1-/- 
TFH cells and expressed as a percentage of CD4+FoxP3-.  (C) 
Quantification of TFR cells expressed as a percentage of total CD4 T cells. 
(D) Quantification of TFR cells expressed as a percentage of FoxP3+ CD4 
T cells. (E) Quantification of TFR cells expressed as a percentage of the 
CD4+ICOS+CXCR5+CD19- gate. * P<0.05, ** P<0.005 
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mice for these studies. We chose to use this approach because we could transfer and 
track Tregs in WT recipients.  We wanted to avoid transfer into lymphopenic mice, 
which would have the potential alter differentiation because of homeostatic 
proliferation.  We sorted FoxP3+ Tregs from WT or Pdcd1-/- 2D2 (MOG–specific) 
TCR transgenic FoxP3 GFP reporter mice and transferred 2x105 2D2 WT or Pdcd1-/- 
CD4+CXCR5-FoxP3+ cells into WT recipient mice. We immunized these recipients 
with MOG/CFA and analyzed cells in the draining lymph node seven days later (Fig. 
2.2F). There were a greater percentage (Fig. 2.2G-H) and absolute number (Fig. 2.2I) 
of 2D2 Pdcd1-/- Tregs upregulating CXCR5 and thus differentiating into TFR cells, 
compared to 2D2 WT Tregs. The increased percentage of PD-1-/- TFR cells in the 
immunized transfer recipients was similar, but less pronounced, than the increased 
percentage in TFR cells seen in immunized PD-1 deficient mice (Fig. 2.2D,H). These 
results demonstrate that PD-1 controls differentiation of FoxP3+ Tregs into TFR cells.  
 
Since CD25 (the alpha chain of the IL-2 receptor) is frequently used as a marker for 
Tregs and is important in Treg survival, we next compared CD25 expression on WT 
and Pdcd1-/- TFR cells directly ex vivo after immunization (Fig. 2.4A). Pdcd1-/- TFR 
cells expressed less CD25 than WT TFR cells (Fig. 2.4B). The attenuated CD25 
expression in PD-1 deficient TFR cells is not likely due to decreased activation 
because the expression of the early activation marker CD69 was virtually identical 
on WT and Pdcd1-/- TFR cells (Fig. 2.4C). To compare the proportion of WT and  
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Fig. 2.4. PD-1 Deficient TFR Cells Have Altered Expression of Activation Markers.  (A) TFR 
cell gating strategy.  WT or PD-1-/- mice were immunized with MOG/CFA and draining lymph 
nodes were harvested 7 days later. (B) CD25 expression on WT and PD-1-/- CD4 subsets gated as 
in (A). Overlay histograms of WT and PD-1-/- TFR cells (left) and mean fluorescence intensity 
(MFI) in CD4 subsets gated as in (A) (right).  Data represent means of 5 mice per group.  (C) 
CD69 expression on WT and PD-1-/- CD4 subsets gated as in (A). Overlay histograms of WT and 
PD-1-/- TFR cells (left) and MFI (right).  Data represent means of 5 mice per group.  (D) 
Intracellular staining of cell cycle marker Ki67 in populations as in (A). Overlay histograms of 
WT and PD-1-/- TFR cells (left) and percent Ki67 high (right) in CD4 subsets gated as in (A). 
Ki67 high was defined as the highest intensity peak on WT TFR cells and is denoted by a black 
bar on the histogram.  Data represent means of 5 mice per group.  All data are representative of 
at least two independent experiments. All error bars indicate standard error. * P<0.05, ** 
P<0.005, *** P<0.0005.   
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Pdcd1-/- TFR cells proliferating at day 7 post immunization, we examined Ki67 
expression, a marker widely used to identify cells that are actively dividing 127. WT 
ICOS+ CXCR5- effectors, TFH and TFR gated cells had high expression of Ki67. In 
contrast, the WT CXCR5-ICOS- “naïve” cells, lacking CD69 and CD25 expression, 
had no Ki67 staining consistent with their designation as naïve (Fig. 2.4D). WT TFR 
cells expressed significantly higher levels of Ki67 compared to PD-1-/- TFR cells, 
suggesting that the increased numbers of TFR cells in PD-1 deficient animals reflect 
increased differentiation, and not maintenance, of TFR cells. Ki67 expression was 
similarly greater in WT ICOS+ effectors and TFH cells compared to Pdcd1-/- ICOS+ 
CXCR5- effectors and TFH cells. This points to an overall decrease in cell cycling in 
Pdcd1-/- effector cells at 7 days after immunization. Other Treg markers such as 
CD103 and GITR were not altered on TFR cells in PD-1 deficient mice (Fig. 2.5). 
Additionally, there was low, but significant expression of PD-L1 on WT and Pdcd1-/- 
TFR cells (Fig. 2.5). Together, these data indicate that PD-1 is important in regulating 
numbers of TFR cells in vivo. 
 
PD-1 Deficient TFR cells are Capable of Homing to Germinal Centers  
 
We next compared the capacity of TFR cells from WT and PD-1 deficient animals to 
enter the germinal center (GC) in order to inhibit the GC response. First, we 
evaluated GC formation in lymph node sections harvested 7 days after MOG/CFA  
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Fig. 2.5. WT and PD-1 Deficient TFR Cells Similarly Express PD-L1, CD103 
and GITR. WT or Pdcd1–/– mice were immunized with MOG/CFA and 7 days 
later draining lymph node cells were stained for PD-L1, CD103 and GITR.  
Histograms show CD4+CD19–ICOS+CXCR5+FoxP3+ cells.     
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immunization. GCs were identified by the presence of PNA/GL7 positively stained 
and IgD negatively stained B cell zones (Fig. 2.6A). These GCs were determined to 
be active, based on robust expression of the cell cycle marker Ki67 (Fig. 2.6B). 
Similar to previous reports 115, 116, CD4+FoxP3+ TFR cells could be found within GCs 
of immunized mice (Fig. 2.6C). The FoxP3 protein within the TFR cells was judged 
to be largely nuclear based on its co-localization with the DAPI staining confirming 
true FoxP3 staining (Fig. 2.6D). 
 
We then investigated whether the phenotypically distinct TFR cells from PD-1 
deficient mice were able to migrate to GCs similarly to WT TFR cells, because PD-1 
blockade can prolong the TCR stop signal and decrease T cell migration 128. We 
immunized WT and PD-1 deficient mice with MOG/CFA and 7 days later analyzed 
lymph node sections for IgD, GL7 and FoxP3 expression (Fig. 2.6E). Although the 
average germinal center area (Fig. 2.6F) and numbers of germinal centers per lymph 
node (data not shown) were equivalent in WT and Pdcd1-/- mice, there were slightly 
more FoxP3+ cells (and therefore TFR cells) located within the GC borders in PD-1-/- 
mice as in WT mice (Fig. 2.6G).  However, since this increase is proportional to the 
larger numbers of TFR cells in lymph nodes of PD-1 deficient mice determined by 
flow cytometry, these data demonstrate that PD-1 deficient TFR cells are not 
defective in homing to GCs and can enter the GC similarly to WT TFR cells.   
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Fig. 2.6. PD-1 Deficient TFR Cells are Capable of Homing to Germinal Centers (GCs).  
(A) Micrographs of draining lymph node sections from WT mice immunized with 
MOG/CFA and harvested 7 days later.  Sections were cut and stained for GL-7 (green), PNA 
(red) and IgD (blue).  GCs were identified by PNA and GL7 positive, but IgD negative, 
staining.  GCs are indicated with a white dotted line.  (B) Ki67 staining in GCs.  Sections 
were stained for the cell cycle marker Ki67 (blue), FoxP3 (red) and GL7 (green).  (C) 
Colocalization of CD4 and FoxP3.  Sections were stained for CD4 (blue), FoxP3 (red) and 
GL7 (green).  Box indicates magnification highlighting CD4 positive staining on FoxP3+ 
cells (D) Colocalization of FoxP3 in the nucleus.  Sections were stained with the nuclear 
stain DAPI (blue), FoxP3 (red) and GL7 (green).  Box indicates magnification highlighting 
FoxP3 protein within DAPI positive nuclei.  (E) Comparison of FoxP3+ TFR cells in 
germinal centers of WT and PD-1-/- mice.  Representative GC staining in WT and PD-1-/- 
lymph nodes 7 days after immunization with MOG/CFA.  (F) Average GC area was 
determined by calculating the area within the dotted lines according to materials and 
methods.  Data represent mean area per lymph node of 5 individual mice.  (G) Numbers of 
FoxP3+ cells contained within GCs.  Data represent mean per GC from 5 pooled mice.  (H) 
Quantitation of the distance of each FoxP3+ cell to the GC border.  The distance for each 
FoxP3+ cell in (E) from the GC borders (dotted line in (E)) was calculated as described in 
materials and methods. (I) CXCR5 expression was quantified on WT and PD-1-/- 
CD4+ICOS+CXCR5+FoxP3-CD19- TFH and CD4+ICOS+CXCR5+FoxP3+CD19- TFR cells by 
flow cytometry 7 days after MOG/CFA immunization. Data represent means of 5 mice per 
group. * P<0.05, ** P<0.005, *** P<0.0005.   
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The relative location of FoxP3+ TFR cells within the GC did not differ significantly 
between WT and PD-1-/- TFR cells (Fig. 2.6H). In both WT and Pdcd1-/- mice the 
FoxP3+ cells tended to reside close to the GC border, with more than half of the 
FoxP3+ nuclei being positioned within 10µm of the border. Furthermore, when 
CXCR5 fluorescence was quantified by flow cytometry in TFR cells, there was 
similar CXCR5 expression on TFR cells in the WT and PD-1-/- mice, indicating 
similar potential for these cells to respond to chemokine cues to migrate to GCs (Fig. 
2.6I). However, TFR cells had lower expression of CXCR5 than TFH cells, which 
may indicate why TFR cells reside close to GC borders.  Taken together, these data 
indicate that TFR cells are increased in lymph nodes of immunized Pdcd1-/- mice, and 
these PD-1-/- TFR cells are capable of migrating into GCs to regulate B cell 
responses. 
 
PD-1 deficient TFR cells More Potently Inhibit T Cell Activation 
 
We next compared the function of TFR cells from WT and Pdcd1-/- mice. TFR cells 
express higher levels of GITR on the cell surface than do TFH cells, which allows for 
separation of the TFH and TFR cells in a similar manner to intracellular staining for 
FoxP3 (Fig. 2.7A). For functional studies, we sorted TFR cells from immunized mice 
by taking the lymph node CD4+ICOS+CXCR5+CD19-GITR+ population as TFR cells 
and the CD4+ICOS+CXCR5+CD19-GITR- population as TFH cells (Fig. 2.7B).  
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Fig. 2.7.  PD-1 Deficient TFR Cells Express More IRF4.  (A) TFR cells express high 
levels of GITR.  WT mice were immunized with MOG/CFA and 7 days later lymph 
node cells were isolated and expression of GITR on TFR 
(CD4+FoxP3+ICOS+CXCR5+CD19-, blue) and TFH (CD4+FoxP3-ICOS+CXCR5+CD19-, 
red) was quantified as shown by histogram overlays.  (B) Expression of FoxP3 mRNA 
in sorted TFR (CD4+GITR+ICOS+CXCR5+CD19-), TFH (CD4+GITR-
ICOS+CXCR5+CD19-) and naive (CD4+ICOS-CXCR5-CD19-) cells.  Data represent 
fold change in mRNA normalized to Hprt. (C) Bcl6 expression analyzed by 
intracellular flow cytometry on TFH and TFR cells from WT (blue) and PD-1-/- (green) 
mice. (D-F) mRNA expression of (D) blimp-1/Prdm1 (E) Rorc and (F) Irf4 from sorted 
WT (blue) and Pdcd1-/- (green) TFR and TFH cells and in CD4-ICOS-CXCR5- (naive) 
cells quantified by qPCR analysis.  Data represent means from at least three separate 
experiments in which cells were sorted from lymph nodes of 10 pooled mice. 
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Sorting in this fashion shows robust mRNA for FoxP3 in the GITR+ (TFR) 
population, but essentially no FoxP3 mRNA in the GITR- (TFH) population, 
validating the use of this gating strategy to isolate TFR and TFH cells for functional 
assays. Furthermore, this sorting strategy can be used to compare WT and PD-1 
deficient TFR cells since GITR expression is identical on WT and PD-1 deficient TFR 
cells (Fig. 2.8). 
 
TFR cells express high Blimp1/Prdm1 and moderate levels of Bcl6 115. Bcl6 and 
Blimp1 reciprocally modulate each other 94; Bcl6 inhibition of Blimp1 is essential 
for maintenance of the TFH phenotype, whereas Blimp1 is important in Treg 
homeostasis in general 129, 130. Since relative expression of Bcl6 and Blimp1 
determines function of TFH subsets, we compared Bcl6 expression in TFR cells from 
WT and Pdcd1-/- mice using flow cytometry to analyze intracellular Bcl6 expression 
at the protein level.  Although TFR cells expressed less Bcl6 at the protein level than 
TFH cells, WT and PD-1-/- TFR had similar Bcl6 levels (Fig. 2.7C). We next 
compared the expression of Blimp1 (encoded by Prdm1) on TFR cells from WT and 
Pdcd1-/- mice.  At the mRNA level, we did not find any consistent differences in 
Blimp1/Prdm1 expression between WT and Pdcd1-/- TFR cells (Fig. 2.7D). Since 
FoxP3 can directly interact with and negatively regulate the function of Rorγt 131, at 
least during iTreg differentiation, we also examined Rorc (which encodes Rorγt) in 
WT and Pdcd1-/- TFR cells. Rorc mRNA levels were lower in TFR cells compared to  
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Fig. 2.8. WT and PD-1 Deficient TFR Cells Similarly Express GITR. WT or Pdcd1–
/– mice were immunized with MOG/CFA and 7 days later draining lymph node cells 
were stained and analyzed on an Aria II flow cytometer.   
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TFH cells, but Rorc expression was increased in Pdcd1-/- TFR cells relative to WT 
TFR cells (Fig. 2.7E). In addition, we compared expression of the transcription factor 
IRF4 in WT and Pdcd1-/- TFR cells, since Blimp1 and IRF4 synergistically control 
the differentiation and effector functions of regulatory T cells 129. We found an 
increase in IRF4 mRNA in Pdcd1-/- TFR cells compared to WT TFR cells (Fig. 2.7F). 
 
IRF4 is essential for the suppressive capacity of regulatory T cells 129.  However, it is 
unclear which cell types TFR cells can suppress and no in vitro suppression assay has 
been developed to test this.  Therefore, we designed suppression assays to be able to 
directly compare TFR cells ex vivo from wild-type or knockout mice.  After multiple 
iterations of comparing number of donor mice, ratios of cells in the well and 
concentrations of antibodies to stimulate the cells, we were able to develop assays 
that gave repeatable results. To determine if increased IRF4 mRNA in Pdcd1-/- TFR 
cells translates into an increase in suppression of naïve T cell proliferation, we set up 
an in vitro suppression assay in which we cultured sorted WT GL7- B cells from 
lymph nodes of mice immunized with MOG/CFA, CFSE labeled WT naïve 
CD4+CD62L+FoxP3- responder T cells from unimmunized mice, and either WT or 
Pdcd1-/- TFR cells sorted from mice immunized with MOG/CFA together with anti-
CD3 and anti-IgM (Fig. 2.9A). The responder T cells highly upregulated CD69 after 
3 days of culture with WT B cells. However, when WT TFR cells were added in a 
1:1:1 ratio, the CD69 expression on the responder T cells was much lower, consistent  
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Fig. 2.9. PD-1 Deficient TFR Cells More Potently Suppress Antibody Production. (A) Design 
of assay to analyze capacity of TFR cells to inhibit activation of naïve CD4 T cells.  WT and PD-1-/- 
mice were immunized with MOG/CFA and TFR cells were sorted from draining lymph nodes and 
plated 1:1:1 with CFSE-labeled CD4 naïve WT (CD4+CD62L+FoxP3-) responder cells and WT 
GL7-B220+ B cells from MOG/CFA immunized mice along with anti-CD3 and anti-IgM for 4 
days.  3 days later samples were analyzed by flow cytometry.  (B) PD-1-/- TFR cells suppress 
activation of naïve T cells to a greater extent than WT TFR cells.  T responders from suppression 
assays from (A) were analyzed for CD69 expression (B) and proliferation (C) by measuring CFSE 
dilution.  % divided indicates percent of cells that have gone through at least one division.  (D) In 
vitro IgG suppression assay design. TFR cells sorted as in (A) were plated in a 1:1:1 ratio of TFR 
(CD4+ICOS+CXCR5+GITR+CD19-), TFH (CD4+ICOS+CXCR5+GITR-CD19-), and B (GL-7-B220+) 
cells from draining lymph nodes of MOG/CFA immunized mice in the presence of anti-CD3 and 
anti-IgM for 6 days. Total IgG was measured by ELISA from supernatants. (E) Suppression assay 
using two concentrations of anti-CD3.  (F) PD-1 deficient TFR cells suppress IgG production to a 
greater extent than WT TFR cells at a 1:1 TFR:TFH ratio. Naive (CD4+ICOS-CXCR5-CD19-) cells 
from immunized mice were included as controls. (G) PD-1 deficient TFR cells suppress IgG 
production to a greater extent than WT TFR cells at a 1:5 TFR:TFH ratio. Data indicates means +/- 
standard error of replicate wells and is representative of at least two experiments (B-G). * P<0.05, 
** P<0.005, *** P<0.0005.   
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with the function of TFR cells in suppressing T cell activation (Fig. 2.9B).  CD69 
upregulation was inhibited to an even greater extent in responder T cells that were 
cultured with Pdcd1-/- TFR cells.  Moreover, Pdcd11-/- TFR attenuated the 
proliferation of responder T cells (Fig. 2.9C), in contrast to WT TFR cells, which did 
not inhibit the proliferation of responder T cells during the 3 day culture period.  
Therefore, although TFR cells do not potently suppress naïve T cell activation per se, 
PD-1 deficiency results in slightly better suppression. 
 
Although TFR cells do not potently suppress naïve cells, it may be possible that TFR 
cells are specialized to inhibit TFH-mediated antibody production.  To test this in 
vitro, we designed a separate in vitro assay.  Originally, we thought by supplying any 
T cell help to B cells we could stimulate antibody production in the well that we 
could measure by ELISA.  However, this proved uneffective and activating CD4 T 
cells from lymph nodes with anti-CD3 and supplying anti-IgM to B cells in a well 
did not result in IgG production.   Therefore, although more difficult, we turned to 
sorting TFH cells as stimulators of the B cells.  To assess the capability of TFR cells 
to suppress B cell antibody production in vitro, we cultured WT GL7- B cells from 
lymph nodes of MOG/CFA immunized mice with WT FoxP3- TFH cells sorted from 
lymph nodes of MOG/CFA immunized mice for 6 days in the presence or absence of 
TFR cells sorted from lymph nodes of MOG/CFA immunized mice, anti-IgM and 
anti-CD3 (Fig. 2.9D). WT B cells produced large amounts of IgG when cultured 
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with WT FoxP3- TFH cells plus anti-IgM and anti-CD3 (Fig. 2.9E). No significant 
IgG was present when CD4+FoxP3- naïve T cells were used in these experiments 
(Fig. 2.9F). When TFR cells were added to the wells along with TFH cells, almost no 
IgG was produced. The TFR-mediated suppression was not due to sequestering of 
anti-CD3 because there was equally good suppression at the two doses of anti-CD3 
tested (Fig. 2.9E), and the anti-CD3 could still be found on the surface of the TFH 
cells at the end of the suppression assay (Fig. 2.10). Pdcd1-/- TFR cells suppressed 
IgG production more than WT TFR cells at both a 1:1 (Fig. 2.9F) and a 1:5 (Fig. 
2.9G) TFR:TFH ratio, with PD-1 deficient TFR cells resulting in a 50% greater 
reduction in IgG production compared to WT TFR cells. Taken together, these data 
demonstrate not only that are there increased TFR cells in Pdcd1-/- mice, but that 
these Pdcd1-/- TFR cells have increased suppressive capacity. 
 
PD-1 Controls Blood T Follicular Regulatory Cells  
 
One possible explanation for the increase in TFR cells in lymph nodes of immunized 
PD-1 deficient mice is that Pdcd1-/- TFR cells are unable to exit the lymph node. 
Studies have demonstrated that functional TFH cells can be found in the blood of 
humans as well as mice 88, 98, 100, but whether TFR cells circulate in the blood of 
humans or mice is not yet known. Strikingly, we found a significant population of 
TFH cells, as well as a smaller population of TFR cells, in the blood of WT mice  
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Fig. 2.10. TFR Suppression is Not Due to Anti-CD3 Sequestering.  (A) Suppression 
assays were performed as in Fig. 2.9D and 6 days later cells in the wells were stained 
for CD4 and FoxP3 to identify TFR, TFH and B cells in the well.  (B) Samples were 
further stained with an anti-hamster secondary antibody and in this way anti-CD3 bound 
to the surface of the cells was quantified. 
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immunized with MOG/CFA (Fig. 2.11A-B). When we compared the kinetics of TFH 
and TFR cell expansion in the lymph node and blood of mice following MOG/CFA 
immunization, we found that both TFR and TFH cells increase in the draining lymph 
node of WT immunized mice over a 10 day period. 
 
Importantly, TFH cells, but not TFR cells, increase substantially by percentage in the 
blood over this time (Fig. 2.11B).  Since total T cells increase in the blood during 
immunization, TFR cells do increase, but this increase is proportional to the increases 
in cellularity. Without antigenic stimulus, the blood TFR:TFH ratio is fairly high 
(sometimes greater than 1:1) but upon addition of a stimulus, blood TFH cells expand 
more than  blood TFR cells so that the TFR:TFH ratio is about 1:5.  To investigate 
whether WT blood TFH and TFR cells are quiescent or are actively in cell cycle, we 
compared Ki67 expression in draining lymph node and blood TFH and TFR cells 7 
days after immunization. TFH cells from the draining lymph node had higher Ki67 
expression than those found in the blood (Fig. 2.11C).  Blood TFH and TFR cells and 
draining lymph node TFR cells expressed similar levels of Ki67, which was lower 
than lymph node TFH cells but much higher than naïve T cells.  Thus, TFR cells in 
the blood are equally in cell cycle as the TFR cells that are present in the draining 
lymph nodes.  
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Fig. 2.11.  PD-1 controls circulating blood TFR cells.  (A) Gating strategy to identify circulating TFH 
and TFR cells from blood.  WT mice were immunized with MOG/CFA and blood was collected 7 days 
later by cardiac puncture. TFH and TFR populations were gated as shown.  (B) Quantitation of blood TFH 
and TFR cells following MOG/CFA immunization.  Mice were immunized as in (a) and sacrificed on the 
indicated days.  Blood was collected and cells stained and gated as in (A). (C) Ki67 expression in blood 
and lymph node TFH, TFR and naïve (CD4+ICOS-CXCR5-) cells 7 days after MOG/CFA immunization.  
(D-F) Comparison of blood TFH and TFR cells in WT and PD-1-/- mice immunized as in (A) and harvested 
7 days after immunization.  (D) Blood TFH cells are shown gated on FoxP3-CD4+CD19- (left) and TFR 
cells are shown gated on FoxP3+CD4+CD19- (right).  (E) Quantitation of blood TFH and TFR cells from 
immunized WT and PD-1-/- mice gated as in (D) and expressed as a percent of CD4+CD19- cells.  (F) 
Quantitation of CXCR5- FoxP3+ cells from immunized WT and PD-1-/- mice, expressed as a percentage of 
CXCR5- CD4+ cells. All data indicates means +/- standard error of 5 mice and is representative of at least 
two independent experiments. * P<0.05, ** P<0.005, *** P<0.0005. 
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Next we investigated whether TFR cells in the blood were inhibited to the same 
degree by PD-1 signaling as lymph node TFR cells. We immunized WT and Pdcd1-/- 
mice with MOG/CFA and 7 days later analyzed the blood for TFH and TFR cells.  In 
WT mice ~2-3 percent of CD4+FoxP3-CD19- cells in the blood were TFH cells, but in 
the Pdcd1-/- mice this increased to ~4-5 percent (Fig. 2.11D). This increase in Pdcd1-
/- TFH cells in blood markedly contrasts with the lymph node, where Pdcd1-/- mice 
have similar, if not less, TFH cells compared to WT mice (Fig. 2.2E). Importantly, 
TFR cells comprised ~3 percent of all FoxP3 positive cells in the blood of WT mice, 
but more than 7 percent of FoxP3 positive cells in the blood of PD-1-/- mice (Fig. 
2.11D-E). The increase in FoxP3+ cells seems to be specific to the blood TFR subset, 
as the percentage of FoxP3+ cells in the ICOS+CXCR5- (ICOS+) and ICOS-CXCR5- 
naïve cell gates were not increased in Pdcd1-/- mice (Fig. 2.11F). Taken together, 
these data indicate that both TFR and TFH cells are present in the blood of mice, and 
both subsets are repressed by PD-1 signals. 
 
To investigate whether blood TFH and TFR cells have a central memory phenotype, 
we analyzed surface expression of CD62L and CD44. CD62L (L-selectin) is 
essential in mediating migration of naïve and central memory cells to secondary 
lymphoid organs132 and CD44 is important for survival, differentiation and homing 
of CD4 T memory cells133. Moreover, high CD44 expression on Treg cells has been 
shown to have a positive correlation with suppressive function due to increased 
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expression of IL-10 in CD44hi Treg cells134.  About 60% of WT and PD-1-/- blood 
TFR cells had high expression of CD62L (Fig. 2.12A). This contrasts with the greater 
than 90% of ICOS-CXCR5- naïve cells that had high CD62L expression. 
Interestingly, Pdcd1-/- TFH cells had lower CD62L compared to WT TFH cells, which 
may indicate a lower potential of Pdcd1-/- TFH cells to home to secondary lymphoid 
organs. CD44 was highly expressed on all WT and Pdcd1-/- blood TFR cells, but 
Pdcd1-/- blood TFR cells had slightly lower surface expression (Fig. 2.12B). 
Furthermore, PD-1 was expressed at lower levels on blood TFR cells than lymph 
node TFR cells which may indicate that these cells are less activated since PD-1 
expression is increased in T cells upon activation (Fig. 2.12C). Taken together, these 
data indicate that blood TFR cells can have a central memory homing phenotype 
based on surface expression of central memory surface markers.    
 
The increase in TFR cells in Pdcd1-/- mice led us to investigate which PD-1 ligand is 
critical for controlling lymph node and blood TFR generation. Although many studies 
have analyzed PD-1 ligand expression on B cells and dendritic cells, these studies 
did not analyze similar organs and activation stimuli with the conditions that we are 
using here for TFR stimulation.  Therefore, we first compared PD-L1 and PD-L2 
expression on B cells and DCs present in dLNs of immunized WT mice because both 
B cells and dendritic cells (DCs) contribute to proper TFH differentiation and 
maintenance in the lymph node 90. It is not yet clear whether B cells, DC or both are  
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Fig. 2.12. Blood TFH and TFR Cells Express Central Memory Homing Markers. WT 
and PD-1-/- mice were immunized with MOG/CFA and 7 days later populations from blood 
were analyzed for CD62L (A) and CD44 (B) expression.  (C) PD-1 expression was 
compared on WT and PD-1 deficient mice from draining lymph node and blood TFH and 
TFR cells 7 days after NP-OVA immunization.   
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needed for TFR differentiation and/or maintenance.  To study GC B cells, we 
immunized mice with NP-OVA subcutaneously and 12 days later compared PD-L1 
and PD-L2 expression on FAS+GL7+CD19+ GC B cells, as well as CD138+ positive 
plasma cells (PC) from the dLN. We found that all B cell subsets expressed high 
levels of PD-L1, but only GC B cells expressed high levels of PD-L2 (Fig. 2.13A). 
To quantify PD-L1 and PD-L2 expression on DCs, we immunized mice with NP-
OVA and analyzed DC populations from the draining lymph node 3 days later. Both 
CD8α+ and CD8α- DC populations expressed high levels of PD-L1 and moderate 
levels of PD-L2 (Fig. 2.13B).  A subpopulation of CD8α- DCs expressed high levels 
of PD-L2.   
 
To determine which ligand is important for TFH and TFR generation, we immunized 
WT, Cd274-/- (PD-L1) and Pdcd1lg2-/- (PD-L2) mice with MOG/CFA, and analyzed 
TFH and TFR cells 7 days post-immunization in the draining lymph node and blood. 
The percentages of lymph node TFH cells in Cd274-/- and Pdcd1lg2-/- mice were 
comparable to WT mice (Fig. 2.13C) and Pdcd1-/- mice (Fig. 2.2E). Cd274-/-, but not 
Pdcd1lg2-/- mice, had greater blood TFH cell numbers, which was similar to Pdcd1-/- 
mice (Fig. 2.13E). TFR cells, however, were increased in the lymph nodes as well as 
the blood of Cd274-/-, but not Pdcd1lg2-/- mice (Fig. 2.13D). Similar to Pdcd1-/- mice, 
Cd274-/- mice did not exhibit any increases in non-TFR FoxP3+ effector cells within  
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Fig. 2.13. PD-L1 but not PD-L2 Controls Blood TFR Cells.  (A) PD-L1 and PD-L2 
expression on B cell subsets.  WT mice were immunized with NP-OVA subcutaneously and 
12 days later germinal center B (GC B), GL7-, and plasma cells (PC) from draining lymph 
nodes were analyzed for PD-L1 (top) and PD-L2 (bottom) expression.  (B) PD-L1 and PD-
L2 expression on dendritic cells (DC).  WT mice were immunized with NP-OVA and 3 days 
later CD8α+ DC and CD8α - DC subsets from draining lymph nodes were analyzed for PD-
L1 (top) and PD-L2 (bottom) expression.  (C-E) Lymph node and blood TFH and TFR cells 
in PD-1 ligand deficient mice.  WT, PD-L1-/- and PD-L2-/- mice were immunized with 
MOG/CFA, and 7 days later draining lymph nodes and blood were harvested and analyzed 
for TFH (C), TFR (D) and CXCR5- FoxP3+ (E) CD4 T cells. Data represent means of 5 mice 
per group. All data are representative of at least two independent experiments. * P<0.05, ** 
P<0.005, *** P<0.0005. 
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the blood (Fig. 2.13E). These studies demonstrate that PD-L1, but not PD-L2, is 
responsible for controlling lymph node and blood TFR cells. 
 
Blood TFH and TFR cells require CD28 and ICOS Signals    
 
We further investigated the costimulatory requirements for blood TFR cells, focusing 
on the effects of CD28 and ICOS costimulation on 
CD4+ICOS+CXCR5+FoxP3+CD19- TFR populations in the blood due to the 
important roles of these costimulatory receptors in controlling lymph node TFH and 
TFR cells. Cd28-/- mice are deficient in lymph node TFH and TFR cells 115. Icos-/- mice 
are deficient in lymph node TFH cells 126. We analyzed CD28 and ICOS deficient 
animals for the presence of TFR cells in the lymph nodes and blood 7 days after 
immunization with MOG/CFA. In WT mice, there were fewer TFH and TFR cells in 
the blood compared to the draining lymph node (Fig. 2.14A-B). In order to identify 
TFR cells in ICOS deficient mice, we could not use ICOS as a surface marker.  
Therefore we gated CD4+CD44+CXCR5+FoxP3+ cells as TFR cells, essentially 
replacing ICOS with CD44, which is highly expressed on all TFR cells (Fig. 2.12B).  
Numbers of TFR (and TFH) cells were greatly attenuated in the blood, as well as 
lymph nodes, of ICOS deficient mice (Fig. 2.14A-C). CD28 deficient mice had 
similar severe deficiencies in CD4+ICOS+CXCR5+FoxP3+ TFR and 
CD4+ICOS+CXCR5+FoxP3– TFH cell percentages in both lymph nodes and blood  
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Fig. 2.14. Blood TFR Cells Require ICOS and CD28 Costimulation.  (A) TFH and TFR gating in 
WT and ICOS-/- mice. Mice were immunized with MOG/CFA and 7 days later draining lymph 
nodes (dLN) and blood were harvested.  TFH cells were gated as CD4+CD44+CXCR5+FoxP3-
CD19-, and TFR cells as CD4+CD44+CXCR5+FoxP3+CD19- cells.  TFH (B) and TFR (C) 
quantitation in lymph nodes (dLN) and blood of WT and ICOS-/- mice as in (A). (D) TFH and TFR 
gating strategy in WT and CD28-/- mice. Mice were immunized as in (A) and TFH cells were gated 
as CD4+ICOS+CXCR5+FoxP3-CD19- and TFR cells as CD4+ICOS+CXCR5+FoxP3+CD19-.  TFH 
(E) and TFR (F) quantitation in lymph nodes and blood of WT and CD28-/- mice gated as in (D). 
All data are representative of at least two independent experiments. * P<0.05, ** P<0.005, *** 
P<0.0005. 
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(Fig. 2.14D-F). Thus, ICOS and CD28 supply essential costimulatory signals for TFR 
and TFH cells in the blood as well as the lymph nodes and lack of either 
costimulatory receptor results in almost complete blockade in differentiation of TFH 
and TFR cells.   
 
PD-1 deficient blood TFR cells more potently regulate antibody production in 
vivo.  
 
We next investigated the function of blood TFR cells in humoral immune responses.  
Because TFH cells in human blood can function in B cell activation and antibody 
production in vitro 88, 98, we analyzed whether circulating blood TFR cells contribute 
to suppression of antibody production in vivo. Although genetic approaches could be 
used to block TFR generation, we wanted to distinguish function from differentiation 
to specifically analyze how TFR cells function.  Therefore, we designed transfer 
experiments in which we immunized >20 WT donor mice with NP-OVA 
subcutaneously and 8 days later sorted TFR (CD4+ICOS+CXCR5+GITR+CD19-) and 
TFH (CD4+ICOS+CXCR5+GITR-CD19-) cells from the blood (Fig. 2.15A). This 
approach is technically challenging because of the relatively few blood TFR cells 
(about 1,000 TFR and 4,000 TFH per mouse) that we can obtain by sorting. We 
transferred these cells into Cd28-/- or Tcra-/- mice because they lack both blood and 
lymph node TFH and TFR cells. This approach enabled us to determine if blood TFR  
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 Fig. 2.15. Blood TFR Cells Regulate Antibody Production In Vivo. (A) Experimental strategy to 
assess blood TFH and TFR cell function by transfer of blood TFH and/or TFR cells into mice that lack 
both lymph node and blood TFH/TFR cells. Blood TFH and/or TFR cells were isolated from 20 pooled 
mice immunized with NP-OVA 8 days previously and CD4+CXCR5+GITR-CD19- TFH and 
CD4+CXCR5+GITR+CD19- TFR cells were purified by cell sorting; recipient CD28-/- or TCRα-/- mice 
received either no cells, 4x104 TFH cells, or 4x104 TFH plus 2x104 TFR cells.  One day later recipients 
were immunized with NP-OVA.  12 days later sera were collected and NP-specific antibody titers 
quantified by ELISA.  (B) WT blood TFR cells potently suppress antibody production.  NP-specific 
antibody titers from experiments as in (A) in which WT TFH or WT TFH plus WT TFR cells were 
transferred into CD28-/- recipients.  (C) CD138+ plasma cell percentages in draining lymph nodes of 
CD28-/- recipients following no transfer (Control), Blood TFH transfer (Blood TFH) or Blood TFH plus 
TFR cell transfer (Blood TFH + TFR) 24 days after immunization.  Cells are gated as a percentage of 
CD11b-CD11c-Ly6c- (dump) cells. 
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and TFH cells could regulate humoral responses.  Since the transferred blood TFH and 
TFR cells are the only follicular T cells in Cd28-/- and Tcra-/- recipients, any 
responses in the draining lymph node would be due to trafficking of the blood TFR 
and TFH cells.  Therefore, not only does this approach allow us to study TFR cell 
function separately from differentiation, but also allows us to study blood TFR 
function, without the interference of starting lymph node TFR cells.    
 
Initially, we adoptively transferred 4x104 TFH cells alone or together with 2x104 TFR 
cells into CD28-/- mice (approximately a two-fold higher ratio of TFR:TFH cells than 
is found in blood after immunization). We immunized recipients 1 day later with NP-
OVA and analyzed NP-specific IgG titers 12 days after immunization (Fig. 2.15B). 
Without blood TFH or TFR cell transfer, Cd28-/- mice were unable to produce 
significant amounts of NP-specific IgG (Fig. 2.15B). The transfer of blood TFH cells 
alone resulted in a substantial increase in NP-specific IgG titers.  Transfer of blood 
TFH cells led to substantial production of IgG1, but also smaller increases in other 
isotypes (data not shown). This IgG1 bias is consistent with immunization of WT 
mice with NP-OVA. Significantly, transfer of blood TFR cells along with blood TFH 
cells resulted in robust inhibition of NP-specific antibody production, demonstrating 
the potent regulatory capacity of blood TFR cells in suppressing antibody production 
(Fig. 2.15B). To evaluate the impact of TFR cells on plasma cell generation, draining 
lymph nodes, spleens and bone marrow were harvested 24 days after immunization 
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and plasma cells were quantified. CD138+ plasma cells were absent from the lymph 
nodes of immunized Cd28-/- mice (Fig. 2.15C-D). Transfer of blood TFH cells 
resulted in a sizable population of plasma cells in the draining lymph node, spleen 
and bone marrow (Fig. 2.15C-D). Blood TFR cells almost completely prevented 
plasma cell formation/survival in all organs analyzed.  
 
Next we transferred blood TFH and/or TFR cells into Tcra-/- recipients. Transfer of 
4x104 TFH cells resulted in high levels of NP-specific IgG and at a greater titer than 
an immunized WT mouse in most experiments (Fig. 2.16A). The robust antibody 
production elicited by blood TFH cells depends on the “follicular program” because 
transfer of total CD4 T cells from CXCR5-/- mice nor CD4+CXCR5-FoxP3- naïve 
cells resulted in near background levels of antibody production in these experiments 
(Fig. 2.16A). When blood TFR cells were transferred together with blood TFH cells, 
the NP-specific antibody titers were markedly reduced, demonstrating the 
suppressive capacity of these cells (Fig. 2.16A).  The blood TFR cells resulted in both 
lower plasma cell percentages in the spleen (Fig. 2.16B), as well as lower 
percentages of TFH cells within the lymph node (Fig. 2.16C). When we compared the 
functions of blood TFH cells and draining lymph node TFH cells following transfer 
into Tcra-/- recipients, we found that blood TFH cells have an increased capacity to 
promote NP-specific IgG production (Fig. 2.16D). TFR suppression of TFH cells also 
depends on the “follicular program” in these cells because neither blood  
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Fig. 2.16. TFR Cell Regulation of Antibody Production Depends on The Follicular Program (A) 
Blood TFH and/or TFR Transfer into TCRα-/- recipients using experimental design as in (Fig. 2.12A). 
Comparison of NP-specific antibody titers in (1) WT control mice, (2) TCRα-/- recipients given no 
cells, (3) TCRα-/- recipients given WT blood TFR cells alone, (4) TCRα-/- recipients given total blood 
CD4 T cells from CXCR5-/- mice immunized with NP-OVA 8 days previously, (5) TCRα-/- recipients 
given blood CD4+FoxP3- cells from unimmunized FoxP3-GFP mice, (6) TCRα-/- recipients given WT 
blood TFH cells, and (7) TCRα-/- recipients given WT blood TFH cells plus TFR cells. NP specific IgG 
levels were determined by ELISA. (B) CD138+ plasma cells from the spleen (gated as a percent of 
live cells) and (C) CD4+FoxP3- TFH cells from the draining lymph node pre-gated on CD4+FoxP3- 
were quantified from experiments in (A) 12 days after secondary immunization.  Error bars indicate 
standard error of at least three separate experiments. (D) Blood TFH cells can have an enhanced 
ability to stimulate antigen-specific antibody production compared to lymph node TFH cells.  Blood 
TFH cells and draining lymph node TFH cells were isolated from WT mice immunized with NP-OVA 
8 days previously and 4x106 cells were transferred into TCRα-/- mice and immunized as in (A).   (E) 
Blood TFR cell suppression is aided by the follicular program.  Blood TFH cells were transferred to 
TCRα-/- mice along with blood CXCR5- FoxP3 GFP+ cells from FoxP3 reporter mice or blood TFR 
cells. Antibody titers were quantified 12 days after NP-OVA immunization and NP IgG levels are 
expressed as a percent of TFH transfer group.  Data indicate standard error of at least three 
independent experiments. 
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CD25+CD62L+ Tregs from Cxcr5-/- mice (data not shown) nor blood CXCR5- FoxP3 
GFP+ Tregs from FoxP3 reporter mice possess the same suppressive capacity as WT 
blood TFR cells (Fig. 2.16E).  Interestingly, although there was a wide range of 
antibody titers, transfer of CXCR5– Tregs seemed to lead to an increase in antibody 
titers.  We found that within this range that there was a correlation between lower 
antibody titers and small amounts of differentiation in TFR cells.  Thus, if we had 
been able to block TFR generation completely in these assays we may have seen even 
greater antibody titers when non-TFR blood Tregs were transferred along with blood 
TFH cells.   
 
Finally, we investigated the suppressive capacity of PD-1 deficient blood TFR cells 
in vivo since we have found that PD-1 deficient lymph node TFR cells more potently 
suppress antibody production in vitro. We adoptively transferred 4x104 blood TFH 
cells alone or together with 1.5 x104 blood TFR cells from WT or PD-1 deficient 
mice into either Cd28-/- or Tcra-/- recipients and immunized as in Fig. 2.15A. PD-1 
deficient TFR cells inhibited antibody production to a greater extent than WT TFR 
cells in Cd28-/- (Fig. 2.17A) as well as Tcra-/- (Fig. 2.17B) recipients, demonstrating 
that they have increased suppressive capacity. The increased suppression was more 
evident in Tcra-/- than Cd28-/- recipients, but PD-1 deficient TFR cell transfers always 
resulted in less antibody production compared to WT TFR transfers. Together, these  
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Fig. 2.17. PD-1 Deficient Blood TFR Cells More Potently Regulate Antibody 
Production In Vivo.  Experiments were performed as in Fig. 2.12.A.  4x104 WT 
blood TFH and 1.5x104 WT or PD-1 deficient blood TFR cells from mice 
immunized with NP-OVA 8 days previously were transferred into CD28-/- mice (A) 
or TCRα-/- mice (B). Recipient mice were immunized with NP-OVA, and NP 
specific antibody titers were measured from serum 12 days later.  Data are 
representative of two independent experiments.   
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data show that blood TFR cells potently inhibit antibody production in vivo and PD-1 
deficiency results in enhanced TFR cell suppressive capacity.
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Discussion 
 
The immunoregulatory functions of the newly defined T Follicular 
Regulatory cell subset are only beginning to be elucidated. Relatively little is known 
about how these cells differentiate and function. A mechanistic understanding of TFR 
cell differentiation and function is needed to gain insight into how humoral immune 
responses are regulated by TFH and TFR cells. Although TFR cells originate from 
different precursors than TFH cells, TFR and TFH cells have nearly identical surface 
receptors. The shared expression of ICOS, CXCR5 and PD-1 by TFR and TFH cells 
means that functional studies of TFH cells have, in fact, examined mixtures of 
stimulatory TFH cells and inhibitory TFR cells. This explains, in part, why TFR cells 
have only recently been identified, even though TFH cells have been studied for over 
ten years.  The PD-1 pathway regulates many effector arms of the immune response, 
however biological complexity has lead to inconsistencies regarding the role of this 
pathway in humoral immune responses 110-114.  
 
In this study, we identify a new mechanism by which PD-1 regulates humoral 
immunity: PD-1 controls the generation and function of suppressive TFR cells. We 
found that lack of PD-1, or its ligand PD-L1, resulted in greater numbers of TFR cells 
in the draining lymph node of immunized mice. These PD-1 deficient lymph node 
TFR cells expressed more IRF4 and showed an enhanced ability to suppress antibody 
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production. We also discovered that TFR cells are present in the blood of mice, and 
that PD-1 controls the numbers of blood TFR cells, as evidenced by the substantial 
increases in PD-1 deficient mice. Importantly, we demonstrated a functional role for 
blood TFH cells in promoting antibody production and blood TFR cells in suppressing 
antibody production in vivo. PD-1 deficient blood TFR cells more potently suppress 
antibody production compared to WT blood TFR cells. Thus, PD-1 limits the 
development and function of TFR cells in lymph nodes and in the circulation (Fig. 
2.18).  
 
We have found that PD-1 signaling inhibits the numbers of TFR cells, but not TFH 
cells, in the lymph node, skewing the TFR to TFH ratio. It is possible that the greater 
suppressive capacity of PD-1 deficient TFR cells, together with the increased ratio of 
TFR to TFH cells in PD-1 deficient mice, results in inhibition of PD-1 deficient TFH 
cells. Alternatively, there may be alterations in PD-1 deficient TFH cells that promote 
their departure from the lymph node and homing to other sites to perform effector 
functions. These hypotheses are not mutually exclusive. We hypothesize that the TFH 
cells in PD-1 deficient mice have increased stimulatory capacity on a per cell basis, 
which partially balances the increased suppressive capacity of the PD-1 deficient 
TFR cells. Increased numbers of TFH cells in the blood of PD-1 deficient mice 
supports this idea because within the circulation, there is less TFR contact with TFH 
cells that may lead to less suppression.  Therefore, the phenotype of the PD-1  
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Fig. 2.18. Expanded role of PD-1 in TFR differentiation and 
function. Data indicate that PD-1 has at least three roles during 
the differentiation and effector function of TFR cells.  First, PD-
1 expressed on the natural Treg (nTreg) inhibits differentiation 
into TFR cells.  When PD-1 signaling is lacking, TFR 
differentiation is increased.  Second, PD-1 signaling on the TFR 
cell inhibits suppressive capacity.  Lacking PD-1 results in an 
increased ability to suppress antibody production.  Third, PD-1 
signaling inhibits egress out of the lymph node.  Lacking PD-1 
results in increased numbers of cells in the circulation.  
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deficient mouse regarding humoral immunity is not straight forward.  Indeed, there is 
much conflicting data as to the role of the PD-1 pathway in humoral immunity.  
Some studies have described increases in lymph node/spleen TFH cells in PD-1 
deficient mice; however the contribution of TFR cells in these studies was not 
assessed 110, 112, 113.  It is likely that increased TFR cells in PD-1/PD-L1 deficient mice 
may have contributed to the increases in TFH cells observed in these studies, and may 
explain, at least in part, conflicting data regarding the role of PD-1 in regulating TFH 
cells and germinal center reactions. For example, Kawamoto et al. described 
increased CD4+CXCR5+ (TFH) cells in the Peyer’s patches of PD-1 deficient mice112.   
However, upon transfer, these cells were non-functional in supporting IgA 
production.  Increases in TFR cells contained within the TFH gate in PD-1 deficient 
Peyer’s patches may explain these data. However, it is still not yet clear if TFR cells 
play a role in controlling IgA production in the intenstine.   
 
Our TFR cell data would suggest that PD-1 deficient mice would have suppressed 
humoral responses.  In agreement with this, Shlomchik and colleagues showed that 
PD-1 deficient mice have deficiencies in the number of long-lived plasma cells, 
resulting in overall lower antibody titers compared to WT mice110.  Interestingly, this 
study described a similar phenotype in both PD-1, PD-L1 and PD-L2 deficient mice.  
Moreover, Finnegan and colleagues also showed that in PD-L1 knockout mice there 
was less antigen-specific antibody titers in a proteoglycan-induced arthritis model in 
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PD-L1 deficient mice111.  Interestingly, although overall proteoglycan antibody titers 
were attenuated in this study, overall arthritis score was increased.  This is probably 
due to the role of PD-1 in controlling the potency of effector T cells within tissues, 
and illustrates nicely the biological complexity surrounding the PD-1 pathway 
because PD-1 can inhibit both pro-inflammatory and anti-inflammatory effector 
cells.  It is possible that different antigenic stimuli and different anatomical locations 
may lead to opposing phenotypes depending on how these conditions influence TFR 
cells.  For instance a viral infection causing a strong inflammatory response may 
cause large expansion of TFH cells while not expanding TFR cells. Therefore, it is 
important to understand the biological cues that are necessary for TFR cell 
development and maintenance so that it is possible to design experimental 
approaches to specifically test the function of TFR cells.    
 
TFR cells depend on SAP, CD28 and Bcl6 for differentiation 115, 116.  However, the 
pathways that limit TFR cell differentiation are less clear. To date, only the 
transcription factor Blimp1 has been shown to inhibit TFR cell differentiation 115.   
Paradoxically, TFR cells express both Bcl6 and Blimp1, two transcription factors that 
reciprocally modulate each other. Naïve T cells that overexpress Bcl6 upregulate 
more CXCR5 and T cells that overexpress Blimp1 are not able to upregulate 
CXCR594. This phenotype is consistent for TFH cells, which do not express Blimp1. 
However for TFR cells, this is paradoxical. It is unclear how a transcription factor, 
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such as Blimp1, that is highly expressed by TFR cells and is also necessary for Treg 
survival, can inhibit TFR cell differentiation. Blimp1 suppresses TFH development by 
directly inhibiting Bcl6.  Therefore, it is possible that the increased TFR cells in 
Blimp1 deficient mice is due to a dependence of TFR cell differentiation on help 
from TFH cells, and not a Treg-intrinsic mechanism. In support of this notion, SAP 
deficient mice lack both TFH and TFR cells, however, SAP is only expressed by TFH 
cells, but not TFR cells (Sage, data not shown).  Analysis of mice with conditional 
deficiency of Blimp1 and/or SAP only on T regulatory cells through use of a FoxP3-
Cre would be a beneficial approach for studying if TFR cells depend on TFH cells for 
differentiation. 
 
Data presented here show PD-1 as the first surface receptor that inhibits TFR cell 
development and function. We also show that PD-1 predominantly interacts with 
PD-L1, and not PD-L2, to inhibit TFR cell generation. Our adoptive transfer studies 
demonstrate a cell-intrinsic role for PD-1 in TFR cell differentiation from FoxP3+ 
Treg cells. Therefore, the increase in TFR cells in PD-1 deficient mice appears to 
reflect increased differentiation and not the maintenance of these cells. We observed 
a general trend for a decrease in cell cycling of CD4 PD-1-/- effector cells, because 
ICOS+CXCR5+FoxP3- and ICOS+CXCR5- effector cells also had diminished Ki67 
expression, at least at day 7 after immunization, which may temporally correspond to 
a maintenance phase. Based on these data, we hypothesize that, rather than simply 
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inhibiting responses, the PD-1:PD-L pathway can act as a molecular switch that 
controls cell fate decisions in naïve CD4 T cells. Integration of signals through PD-1, 
the TCR and cytokine receptors may direct CD4 T cell subset differentiation. 
Likewise, PD-1 may limit differentiated effector T cell expansion, cytokine 
production and/or survival depending on how signals through the TCR, PD-1 and 
cytokine receptors are integrated. Thus, the PD-1 pathway can influence CD4 T cell 
lineage commitment in distinct ways, depending on molecular cues and the local 
environment.   
 
For instance, PD-L1 can promote induced Treg (iTreg) differentiation from naïve T 
cell precursors 103-107, 135. However, we find that PD-1 inhibits differentiation of TFR 
cells. TFR cells arise from natural T regulatory cell (nTreg) precursors (shown here 
and previously 115). Therefore, our studies suggest that PD-1 may have distinct roles 
in iTreg and nTreg differentiation.  Moreover, TFR cells are one of the only defined 
effector nTreg subsets.  It will be interesting to determine if PD-1 also inhibits other 
nTreg effector cells, which have roles other than suppressing B cell function. 
However, it is technically challenging to study the distinct roles of PD-1 on nTreg 
and iTreg cells since methods for discriminating nTreg and iTreg cells in vivo are 
still being developed.  In addition genetic background may contribute to the affects 
of PD-1 deficiency. These studies were performed with C57Bl/6J mice, without any 
autoimmune susceptibility mutations. We use a combination of self-antigen (MOG) 
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and foreign antigen (NP-OVA) for these studies.  However, it is possible that 
autoantibody-prone models, such as mice that have Fas mutations, may limit the 
effectiveness of TFR cells and result in increased antibodies due to a predominant 
TFH phenotype.  In support of this, it has been shown that PD-L1–/– mice have 
decreased survival when on the MRL-Faslpr background 136. MRL-Faslpr mice 
produce large quantities of autoantibodies, however, the phenotype in the PD-L1 
deficient mice on this background may be due to effector T cells and may not be 
necessarily antibody-mediated. Conditional knockout strategies where PD-1 is 
deleted only T regulatory cells may help to solve this unresolved question.    
 
Here we find that blocking the PD-1 pathway leads to increased functionality of TFR 
cells.  Increased functionality during PD-1 blockade is also a phenotype for 
exhausted T cells.  It has been previously shown that PD-1 is highly expressed on 
exhausted T cells during chronic viral infection with LCMV 137.  In the setting of 
chronic viral infection, PD-1 mediates exhaustion of CD8 effector cells, preventing 
them from effectively responding to viral antigens.  When PD-1 was blocked with a 
PD-L1 blocking antibody, the CD8 effector cells partially regained their ability to 
respond to viral antigens and more potently cleared virus.  PD-1 also can inhibit CD8 
T cell functionality within the tumor microenvironment 138 and it can inhibit CD4 
and CD8 T cell functionality in the setting of HIV infection 139.  Therefore, PD-1 
suppression of function is relevant on multiple cell types. TFR cells similarly have 
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increased functionality when the PD-1 pathway is blocked.  However, TFR cells do 
not seem to be exhausted like the CD8 or CD4 T cells in chronic viral infection 
because TFR cells are actively proliferating within the germinal center, as evidenced 
by  Ki67 expression.   
 
PD-1 and its ligands also have key roles in mediating tolerance 119 140.  PD-1 is also 
be expressed on other cell type such as B cells, monocytes and myeloid DCs 2.  
Therefore, bidirectional signaling may be possible between T cells, B cells and DCs 
since all three cells can express PD-1 and PD-L1.  Although PD-1 inhibits B cell 
signaling through the B cell receptor, the role of PD-1 on B cells in vivo is still not 
yet clear 141.  Although we demonstrate a T cell-intrinsic mechanism by which PD-1 
acts on nTregs in in vivo adoptive transfer models, it is possible that PD-1 deficiency 
on the B cell may have a role in the phenotype of increased TFR cells in the PD-1 
knockout.  Determining if PD-1 has a role on B cells during the 
generation/maintenance of TFR cells could be assessed by enumerating TFR cells in 
adoptive transfers in which wild-type or PD-1 deficient B cells are transferred along 
with CD4 T cells into RAG deficient mice.   
 
Because of the recent discovery of TFR cells, there is a lack of fundamental 
knowledge about TFR cell biology, so we developed novel assays to analyze 
mechanisms by which PD-1 regulates TFR cell function. TFR cells have the potential 
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to directly inhibit actition of naïve T cells, TFH cell function, and/or B cell activation. 
Additionally, TFR cells may regulate TFH or B cell responses either inside the B cell 
follicle and/or control activation and differentiation of T cells outside the B cell 
follicle. Here, we present the first specific assays for TFR cell function in vitro and 
show that sorted wild type TFR cells from the lymph node are extremely potent at 
inhibiting antibody production, but not very effective at suppressing activation of 
naïve T cells. Therefore, TFR cells seem to be specific for inhibiting humoral 
responses.   
 
The specificity of TFR cells for inhibiting humoral responses makes them attractive 
targets for therapy.  PD-1 deficient TFR cells inhibit naïve T cell activation and 
attenuate antibody production in vitro to a greater extent than WT TFR cells. 
However, the mechanism by which TFR cells exert their suppressive functions has 
not been fully investigated.  TFR cells produce large amounts of IL-10, but this does 
not seem to be the mechanism of suppression, because preliminary experiments 
blocking IL-10 in vitro does not appear to alter the suppressive function of TFR cells 
(Sage, data not shown).  Moreover, blocking IL-10 with a neutralizing antibody does 
not attenuate TFH cell numbers (Sage, data not shown). More experiments are needed 
to determine the exact mechanism of suppression.  There are many ways Tregs are 
thought to suppress cells such as through direct cytolysis, IL-2 sequestering and 
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production of IL-10 or TGF-β.  Each one of these mechanisms will need to be tested 
individually to determine how TFR cells suppress TFH cells and B cells.   
 
Our studies demonstrate the dynamic control of antibody production by lymph node 
TFH and TFR cells. Initially, our attempts to activate B cells to produce antibody in 
vitro with total CD4+CXCR5+ cells resulted in little IgG secretion. However, when 
we separated TFH cells from TFR cells and used pure TFH cells in such experiments, 
we could detect robust IgG production. Of note, during an immune response to 
peptide/CFA, the in vivo dLN TFR:TFH ratio is ~1:5.  When we cultured TFR and TFH 
cells at this ratio in our in vitro suppression assay, little antibody production was 
observed.  This ratio should mirror the suppressed humoral immune response in vivo. 
These data may help to explain why in vitro antibody assays have not been widely 
used to quantitate B cell function previously.     
 
TFR cells tend to be present predominantly at the borders of germinal centers, which 
may be explained by their relatively lower expression of CXCR5 compared to TFH 
cells and B cells, though other chemokines also may have roles. It is possible that 
close proximity of TFR cells to germinal center borders enables them to interact with 
TFH cells as they enter.  This could make TFR cells the “gate-keepers” of the 
germinal center, inhibiting TFH cells as they enter and gain access to B cells 
undergoing somatic hypermutation and class switch recombination. The relative 
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lower expression of CXCR5 of TFR cells compared to TFH cells supports their 
positioning at the border of the germinal center.  However, there are probably other 
unidentified chemokine receptors that may modulate positioning of these cells. The 
close positioning of TFR cells to the germinal cener border may provide a mechanism 
that inhibits autoimmunity, because without suppression of the TFH cell just as it 
enters the GC, the threshold for B cell activation may be lower.  Lowering the 
threshold for a B cell response may lead to autoimmune antibody formation.  In 
support of this, it has been hypothesized that TFR cells predominantly limit non-
antigen specific antibody production115, however our results provide evidence for 
antigen specificity of TFR cells since these cells expand in our recipients when we 
immunize the mice with NP-OVA.  However, more experiments are needed to test 
the antigen specificity of the TFR cells in a more definitive manner.  
 
Our studies suggest that the balance between TFR and TFH cells (and not individual 
numbers of each) within the germinal center itself may modulate the type and extent 
of humoral responses. The relative roles of TFR and TFH cells also may depend on 
the source or strength of antigenic stimulus, cytokine milieu, and tissue 
microenvironment, and further work is needed to investigate these issues.  It will be 
interesting to compare different adjuvants to determine if some classes of adjuvants 
preferentially elicit expansion of TFH cells compard to TFR cells or vice versa.  This 
information could be useful in rational design of vaccines.   Two other adjuvants that 
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were tested in the course of these experiments were sheep red blood cells (SRBCs), 
which are classically used in mouse in vivo models, and Aluminum Hydroxide 
(Alum) which is a potent adjuvant used in vaccination of humans.  In the case of 
SRBCs, which is an odd stimulus since it induces a xenograft response yet 
nevertheless elicits huge germinal center B cell numbers, both TFH and TFR cells are 
expanded greatly.  In the case of Alum, there is a very small amount of TFH and TFR 
differentiation and both subsets seem to polarize equivalently. Clearly, more 
experiments need to be performed.  There is an increasing literature on the role of 
toll-like receptors (TLRs) during vaccination142 and sequential analysis of individual 
innate signals (individual TLRs, NLRs, etc) on B cells and DCs in the differentiation 
of TFH and TFR cells is a priority.   
 
Surprisingly, we found substantial populations of TFR cells in the blood of mice. 
There are a number of reports describing TFH cells in the circulation of humans 88, 98 
and one in mice 100. To our knowledge, our work is the first description of TFR cells 
in the blood of any organism. In humans, blood TFH cells have been shown to 
provide B cell help for the production of antibody in vitro. Some studies show more 
efficient B cell antibody production by blood TFH cells compared to blood CXCR5- 
cells 88, 98 whereas other studies find no differences between blood TFH and CXCR5- 
cells 143. Differences might relate to mixtures of blood TFH and TFR cells and their 
relative ratios in these experiments.  Since most work describing blood TFH cells was 
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done in humans, little is known about the requirements for blood TFH differentiation 
and function. Here we show that murine blood TFH and TFR cell generation requires 
signals through ICOS and CD28, two costimulatory receptors essential for 
controlling TFH cells in the lymph node. Previous work showed that CD28 is 
essential for TFR cells in lymph nodes 115. Here we demonstrate lymph node TFR cell 
generation also requires ICOS signaling. However, as previously mentioned, if TFR 
cell differentiation partially depends on TFH development, then it is still unknown 
whether CD28 and ICOS have Treg-intrinsic roles in TFR differentiation.  
Conditional knockouts could be used to  investigate these questions. 
 
Our transfer studies show that blood TFR cells are functional and can regulate 
antibody production in vivo. To study TFH and TFR function, we transferred blood 
TFH cells alone or with TFR cells into Cd28-/- or Tcra-/- mice, which lack both blood 
and lymph node TFH and TFR cells. Although technically challenging, this approach 
allowed us to analyze TFH and TFR cell function separately from differentiation. Our 
transfer studies demonstrate effective and specific control of humoral responses by 
blood TFH and TFR cells. Blood TFR cells are extremely potent at inhibiting TFH cell 
mediated antibody production, even when relatively few cells are transferred.  
 
We hypothesize that blood TFR cells may represent a central memory pool that can 
be utilized to modulate humoral immunity, analogous to recently reported FoxP3+ 
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cells with regulatory memory to self-antigens 144 and similar to a proposed role for 
blood TFH cells 88. High expression of CD62L and CD44 on blood TFR cells along 
with their ability to home back to lymph nodes strongly support this idea. Blood TFH 
cells may migrate to lymph nodes and interact with cognate B cells rapidly upon 
antigen exposure, whereas naïve T cells need at least two to four days to differentiate 
and upregulate CXCR5.  This would make the blood TFH memory cells the “first 
responders” and may help direct the extent of a humoral response. Additionally, 
blood TFR cells homing to lymph nodes would be able to suppress early B cell 
responses, before dLN nTregs could fully differentiate into TFR cells.   
 
The function of blood TFR cells may also be to ensure systemic control of humoral 
immune responses.  For instance, if a self-reactive humoral immune response is 
initiated in a specific lymph node, the TFR cells primed there may be able to 
distribute through the circulation to other secondary lymphoid organs in order to 
prevent subsequent reactions to self antigen that may be present in multiple 
locations.  Moreover, antibody secreting cells (ASCs) have been demonstrated to 
migrate and reside within tissues such as the skin and gut 145, and it is possible that 
TFR cells may also migrate to these locations in order to control antibody production 
from these ASCs.  Thus, TFR cells may have expanded roles outside of lymphoid 
organs.  Further work is needed to determine if TFR cells that migrate to tissues 
maintain their CXCR5 expression and develop methods to track these cells.     
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During the germinal center reaction, B cells can differentiate into memory B cells 
that persist for long periods of time or plasma cells that circulate and produce large 
amounts of antibody.  Beyond their ability to directly suppress antibody responses, 
TFR cells may be instrumental in determining B cell fates and control whether an 
immune response generates plasma cells or memory B cells. For example, cytokines 
produced by TFR cells may direct GC B cell differentiation into memory B cells and 
away from plasma cells. We observed strong reductions in plasma cell numbers in 
our transfer experiments in which wild-type TFR cells were transferred along with 
wild-type TFH cells into CD28 deficient mice supporting this idea. PD-1 and PD-1 
ligand deficiency result in decreased numbers of long-lived plasma cells 110, and 
further work is needed to determine if this is related to enhanced TFR cell numbers 
and suppressive capacity in PD-1 deficient mice.  If TFR cells can direct B cell fates, 
this would have implications for rational design of vaccines. For instance, by 
transferring TFR cells or selectively boosting TFR cells during vaccination, it may be 
possible to divert the B cell lineage development into memory B cells, producing 
less antibody production in the short term while generating greater responses in the 
long term.   
 
It also will be interesting to determine if inappropriate B cells responses may result 
from altered TFR function.  For instance, elderly individuals tend to have reduced 
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antibody generation and do not develop long-lived plasma cells during vaccination 
leaving them more susceptible to infections146.  This may be due to increased TFR 
function, decreased TFH function, or both.  Moreover, it is also possible that TFR 
cells may be instrumental in preventing systemic autoimmunity, and underlie many 
systemic autoimmune diseases.  For example, there may be deficiencies in TFR cell 
function leading to heightened TFH responses in these diseases. Therefore, measuring 
TFH and TFR cell ratios within the blood may be a worth-while diagnostic tool.  This 
information may also be important for developing therapeutic strategies using TFR 
cells. By expanding either TFH or TFR cells from patient blood in vitro, it may be 
possible to enhance antibody responses by transferring TFH cells or to inhibit 
systemic autoimmunity by transferring TFR cells.  
 
In summary, we define a new role for PD-1 in regulating immune responses, by 
inhibiting differentiation and function of T follicular regulatory cells in both lymph 
node and blood. A better understanding of TFR and TFH interactions has the potential 
to provide novel insights into mechanisms that regulate humoral immunity. Whether 
TFH and TFR cells regulate memory B cell responses is unknown and such 
knowledge may enable novel vaccination strategies to enhance humoral immunity. 
Further understanding of how PD-1 regulates humoral immunity may suggest 
strategies for manipulating this pathway to enhance protective immunity and long-
term memory or to inhibit systemic autoimmunity.  
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Chapter 3.  General Discussion 
 
At a first glance the two studies presented here seem far removed.  How can studying 
the intimate details of TCR signaling in vitro relate to the functions of a specific 
subset of Tregs in modulation of antibody responses in vivo?  The two subjects are 
closer than they appear.  At the heart of both studies is the requirement for T cells to 
be properly activated.  In the case of sensing antigen in vitro, T cell ILPs are 
responsible for identifying and responding to cognate antigen. Without ILPs, 
memory T cells cannot efficiently respond and flux calcium, leading to inefficient 
activation.  
 
The requirement for sensing antigen can also be applied to TFR cells.  In order for 
TFR cells to develop, the nTreg cells need to find and respond to antigen, presumably 
via dendritic cells within the T cell zone. Before this process can occur, the nTreg 
must get into the lymph node by transmigrating through the high endothelial venules. 
Since CD4 T cells use ILPs to transmigrate through the endothelium, it seems likely 
that the nTreg will already have ILP machinery in use when it comes into contact 
with DCs.  When the nTreg locates a DC, it must be efficiently activated in order to 
differentiate.  We hypothesize that in this setting it is the ILPs on the nTreg cells that 
provide efficient antigen recognition so that the nTreg can initiate the TFR 
differentiation program.   
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TFR sensing of antigen with ILPs is most likely necessary during the initial priming 
of the natural T regulatory cells into TFR cells as well as during effector function 
later in the B cell zone.  Here we show that ILPs are relevant both during CD4 T 
interaction with dendritic cells as well as B cells.  Since TFR cells reside in the B cell 
follicle during immune responses, they almost certainly would be able to use ILP 
structures to probe B cells looking for antigen.  In addition, it is possible that the 
close membrane-membrane contact that the ILPs elicit may be responsible for 
directed cytokine production to the B cells by the TFR cells.  If TFR cells have ability 
to directly lyse B cells, the ILPs may also deliver cytotoxic granules.  Without the 
close membrane contact, TFR suppression may suppress or injure bystander cells 
leading to adverse pathologies.   
 
The studies of TFR cells also demonstrate nicely the need for regulated T cell 
activation, which can be controlled properly by ILPs.  For instance, dysfunctional 
ILPs lead to inefficient antigen recognition, leading to reduced T cell activation.  Our 
in vivo models nicely demonstrate how altered T cell activation can change an 
immune response.  PD-1 signaling results in dephosphorylation of proximal TCR 
signaling which is functionally similar to disturbing ILP formation, because 
downstream TCR responses such as calcium flux are attenuated in both.  In the case 
of TFR cells, we demonstrate here that decreased TCR signaling (via PD-1) limits 
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TFR differentiation, suppression and exit from the lymph node.  Thus, we can 
speculate that weakened ILP function specifically on regulatory cells could limit TFR 
generation, and therefore lead to increased antibody production that may lead to 
autoimmune disease. My work illustrates how lessons from separate areas of 
immunology can be used together to understand immunity. 
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